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Figure 1. A schematic of PDT treatment of cancer: a) non-active form of drug is administered; b) 
drug is left to accumulate in tumour and healthy tissue; c) specific radiation of tumour tissue leads 
to production of singlet oxygen/ reactive oxygen species leading to targeted cell death. Top left: 
Depth of tissue penetration as a function of wavelength of light, adapted from [2].
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Figure 2. a) Structure of Psoralen and related molecules; b) Structure of 
Photofrin.
Photofrin (porfimer sodium)
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Figure 3. A simplified Jablonski diagram showing typical energy levels and transitions 
relevant to the formation of the triplet state of photosensitiser, and photosensitization of 
molecular oxygen. IC = internal conversion, VR = vibrational relaxation, ISC = 
intersystem crossing.
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Figure 4. TLD1433 and examples of several other Ru(II) diimine photosensitisers. 1 - 4 are 
highly lypophylic compounds, numbered RuL1-RuL4 in [39]; compounds 5 - 7 are highly 
charged (+8) compounds (Ru1 – Ru3 in [40]); compounds 8 and 9 that contain derivatives 
of a known DNA intercalating ligand dppz are compounds 1 and 2 in [41].
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Figure 5. Ru(II) photosensitisers 10 and 11 which in conjunction with single wall 
carbon nanotubes act as dual photothermal anticancer agents (compounds Ru1 
and Ru2 in [42]). Reproduced with permission from the American Chemical 
Society
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Figure 6. Chemical structures of some Ru(II) photosensitisers.  Compound 
12 (Ru65 in [43]) is a DNA intercalator. Compounds 13 - 20 (1 - 8 in [45]) 
contain cyclometallating and diimine ligands. A systematic study of the 
effect of the extending conjugation in either cyclometalalting, or diimine
ligands, on photodynamic properties has been performed.
Figure 7
N
N
N
N
N
N
N
N
Ru
N
N
N
N
N
N
N
N
Ru
Re
N
N
N
N
N
N
N
N
Ru
Re
CO
COOC
Cl
CO
OC CO
Cl
4+
2+
21 22
23
cHSA-PEO-TPP-Ru
24
Figure 7. Chemical structures of some Ru(II) based photosensitisers A 
macrocyclic Ru(II)/Re(I) photosensitiser 21, and its mononuclear Ru(II) 
building block 22 [46]. Ru(II) PS conjugated to human serum albumin (23) 
cHSA-PEO-TTP-Ru and to HSA aa 312 to 324 (24)[47]. Structures of 23 
and 24 and image reproduced from [47] with permission from the American 
Chemical Society.
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Figure 8. Cyclometallated Ir(III) complexes of general type [Ir(C^N)2(NN)]+.
Compounds 25 and 26 are compounds 1 and 2 in [65]; compounds 27 – 32 are 
compounds 1-6 in [56]. Emission images of HeLa cells incubated with 27-31
(left to right) are also shown. Emission images reproduced from [56] with 
permission from the American Chemical Society.
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Figure 9. Chemical structures of metallo-pyrido carbazole
Ir(III) photosensitisers 33 – 41b (compounds 1 - 11 in [69]).
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Figure 10. [Ir(C^N)2(NN)]+ photosensitisers designed with the aim of combining 
photosensitisation with a Histone deacetylases (HDAC) inhibitor, 
suberanilohydroxamic acid (SAHA). Compounds 42 - 45 are compounds 1 - 4 in 
[71]. The bottom panel shows characterisation of apoptosis induced in HeLa 
cells by complex 42 using annexin V-FITC staining, and monitored by flow 
cytometry, reproduced from [71] with permission from the Royal Society of 
Chemistry.
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Figure 11a. Chemical structures of some [Ir(C^N)2(NN)]+ photosensitisers: 
46[73]; 47[74]; 48 - 51 (compounds TIr1 - TIr4 in [76]). 
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Figure 11b.  Chemical structures of Ir(III) compounds 52 and 53.[77] 52 and 53 are 
pH sensitive in the physiological range. 52 has the higher PI index for Ir(III) 
complexes to date under one-photon excitation, and is also a two-photon PDT 
agent[77]. The bottom panel shows two photon absorption activated killing of 
HeLa cancer cells incubated with 52 (1 ȝ0) for two hours, followed by irradiation 
with 760 nm, ~100 fs pulses (irradiated area 225 x 225 ȝP, 1024x1024 pixels, 6.6 
ȝV dwell time, 8 scans) with the powers corresponding to 0, 1088, 1632, 2176 J cm-
2
. Cell apoptosis is indicated in green and necrosis in red. All images are 450 x 450 
ȝP except those in the 0 mW column which are 900 x 900 ȝP. Cell death Images 
reproduced from [77] with permission from John Wiley & Sons.
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Figure 12. Chemical structures of some of Ir(III) photosensitisers: compounds 
54 - 56 are compounds Ir1 – Ir3 in [78]; compounds 57 – 61 are compounds 
Ir-Es, Ir-Me, Ir-Pn, Ir-Pc and Ir-Cz in [79]. Top panel reproduced from [78] 
with permission, Copyright The Royal Society of Chemistry.
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Figure 13. Ir(III) photosensitisers containing fructose, and their fructose-free analogues; 
compounds 62 – 65 are compounds 1a, 1b, 2a and 2b from [80].
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Figure 14. Ir(III) photosensitisers with diverse cyclometallating ligands. Compounds 66 – 69
are compounds 1a, 2a, 1b and 2b from [83].
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Figure 15. Ir(III) photosensitisers which are lysosome-specific (70 and 71, correspond to  Ir-
P(ph)3 and Ir-alkyl from [84]); [Ir(N^C)3]n pH-responsive photosensitisers 72 and 73 (5 and H3.5 
from [85]); and pH-responsive, lysosome-specific [Ir(N^C)2(NN)]+ compounds 74 – 77
(compounds 1 – 4 from [88]).
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Figure 16. Red-light activated Ir(III) photosensitisers bearing BODIPY 
groups, 78 – 81 (compounds Ir-1 – Ir-2 from [89]).
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Figure 17. Systematic tuning of light-absorbing properties of Ir(III) complexes 
through changing conjugation in diimine and cyclometalling ligands, 82 – 87
(compounds 1 – 6 from [90]).
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Figure 18. Ir(III) photosensitisers with PEG chains and their analogs. 
Compounds 88 – 92 are compounds 1a – 5a, compounds 93 – 97 are 
compounds 1b – 5b from [95].
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Figure 19. Ir(III) photosensitisers designed for mitochondrial (98 – 100, 
compounds 1 – 3 from [97]) and perinuclear (101 – 102, compounds 1M and 
1P from [98] ) localisation.
NN
N
N
N
N
N
N
R1
R1
OO
O O
Ru
105 = 2,6-diisopropylphenyl
N
N
N
N
R2
R2
OO
O O
Ir
Cl
+
106 = 3-pentyl
N
N
N N
O
OO
O
N
N
N N
O
OO
O
107 108
2+
Figure 20
N N
Ir
N
N
N
N
R
R +
PF6
-
109: R=H, 110: R=CH3, 111: R=CH3CH2,
112: R=CH3CH2CH2, 113: R=CH3CH2CH2CH2
Figure 20. Orange-absorbing photosensitisers 103 and 104 (Ru-2 and 
Ir-2 from [99]); aromatic acid imide-containing photosensitisers 105 
- 108 (R1, R2, L1 and L2 from [100]); mitochondria-targeting 
photosensitisers 109 – 113 (Ir1 – Ir5 from [101]).
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Figure 21. Pt-based photosensitisers. 114 – 117 are compounds 1 – 4 from [108]; 
compound 118 is compound 1 from [109]. The bottom panel shows a representative 
COMET assay images for HeLa cells treated with 0.5 PM of 118, with and without 
exposure to 405 nm light (3.6 J cm-2) [109].
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Figure 22. Multinuclear Os(II) and Ru(II) photosensitisers 119 and 120 [113]; 
mononuclear Ru(II) and Os(II) photosensitisers 121 and 122 (1 and 2 from [115]).
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Figure 23. Os(II) photosensitisers 123 – 125 (TLD1822, TLD1824 and TLD1829 from 
[29]).  
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Figure 24. Re(I) photosensitisers 126 – 127 (1-4 from [118]). 
Re(I) photosensitisers bearing protein tags, 129 – 132 (Re –NH2, Re-COOH, Re-
NLS and Re-Bombesin from [119]) and fructose unit, 133 - 134 (1 and 2 from 
[120]), and their tag-free analogues.
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Figure 25. Re(I) pyridocarbazole complexes with tuneable absorption maxima for red-light 
activated PDT, 135 – 142 (compounds 1 – 8 from[121]); compounds 138-139 are not PDT-active. 
The bottom panel shows visible-light-induced antiproliferative activity of 140 in HeLa cancer 
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permission from John Wiley & Sons.
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Figure 26. Re(I) photosensitisers 143 and 145 containing BODIPY unit (Re–1 
and Re-2 from [122]).
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Figure 27. Ru(II) photosensitisers 146 (1 in [127]) and 147-149 (2, 3 and 1 in 
[132]), and a control compound 150. Top panel reproduced from [127] with 
permission from the American Chemical Society. 
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Figure 28. Ru(II) photosensitisers 151 and 152 (1 and 2 in [133]) and 153 and 
154 (1 and 2 in [134]).
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Abstract  
Photodynamic therapy (PDT) exploits light-activated compounds for therapeutic use.  It relies 
on a photosensitiser (PS) that is inactive in the absence of light. When irradiated, the PS 
absorbs light and is promoted to a higher energy, “excited” state (PS*), which is either toxic to 
cells in itself, or triggers formation of other species which are toxic to cells, and hence 
particular wavelengths of light can be used to induce light-dependent cell killing. In PDT 
occurring via the so-called type I and type II mechanisms, the PS* engages in energy transfer 
to dioxygen present in cells and tissues. This process generates highly reactive singlet oxygen 
(1O2) and/or other reactive oxygen species (ROS) which in turn cause damage in the immediate 
vicinity of irradiation, and ultimately can lead to cell death.  Whilst the main focus of research 
for the last 50 years has been on organic molecules or porphyrins as sensitisers, there is now 
emerging interest in extending the use of transition metal (TM) complexes can display intense 
absorption in the visible region, and many also possess high two-photon absorption cross-
sections, which enable two-photon excitation with NIR light.  As with any other type of 
photosensitiser, the issues to consider whilst designing a TM complex as a photosensitiser 
include cell permeability, efficient absorption of NIR light for deeper penetration, preferential 
affinity to cancer cells over healthy cells, targeted intracellular localisation, and lack of side 
effects. This review summarises recent developments involving photosensitisers containing, 
Ru(II), Os(II), Pt, Ir(III), and Re(I), and the approaches used to address the above requirements.  
Several remarkable recent advances made in this area, including the first clinical trial of a 
metal complex as a photosensitiser, indicate the bright future of this class of compounds in 
PDT.   
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1. Introduction 
1.1  Photodynamic therapy 
The ultimate aim of drug design and discovery is to find a compound that exerts maximal 
beneficial effects in the target tissue with minimal side effects in other tissues. Yet adverse 
secondary effects are common for most clinically used drugs, and can in part be attributed to 
the lack of specificity of their site of action. Photodynamic therapy (PDT) is built on the 
concept of light-activatable compounds known as photosensitisers (PS) which can be ‘switched 
on’ at the target site by localised irradiation with light. The PS should be non-toxic in the 
absence of light, and thus PDT offers the promise of highly targeted therapy with decreased 
side-effects[1].  
In PDT, the patient is treated with the non-active PS either topically, systemically or by other 
treatment routes such as intravesically, dependent on the condition. The PS is then allowed to 
accumulate throughout the body in both healthy and non-healthy tissue (Figure 1, top left). 
Once peak concentration in the unhealthy tissue is reached, the PS is activated by localised 
irradiation with light of a suitable wavelength, with depth of tissue penetration dependent on 
wavelength of activating light [2] (Figure 1).   
Absorption of light by the PS leads to the population of an electronic excited state, PS*.  A 
currently used classification of the types of PDT is based on the mechanism of action of the 
PS*. Type I and II mechanisms of PDT operate via an oxygen-dependent pathway and are the 
focus of this review. In type III mechanism dependent PDT, electron or hydrogen transfer from 
the PS*, or cytotoxic products from its photodegradation, lead to cell death. These reactions are 
usually classified as photoactivated chemotherapy (PACT)[3] rather than PDT.   
 
The key step in type I and type II PDT is a reaction of the PS* with molecular oxygen (O2). 
This interaction produces singlet oxygen (1O2) or reactive oxygen species (ROS) respectively, 
leading to irreparable cell damage and hence cell death: 
PS + light ĺ  PS* 
PS* + O2 Ѝ PS  + 1O2/ROS Ѝ cell death 
Notably, the PS itself is not changed by this process, it merely acts as an “energy relay” to 
absorb light and transfer energy, therefore the PS can be used in many cycles of light 
absorption.   
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PDT is used around the world to treat a range of ailments from acne[4, 5] to age-related 
macular degeneration[6] as well as in treatment of a subset of cancers[7], often in combination 
with other types of treatment.   
Light therapy is believed to have been employed since ancient times, an example being the 
treatment of vitiligo using plants containing furocoumarin (psoralen) in India and Egypt[8, 9].  
Modern investigations into phototherapy were initiated in the late 19th century by Niels 
Finsen[10] who used a carbon arc-lamp to treat a condition called lupus vulgaris. This 
revolutionary approach to the treatment of diseases led to Finsen being awarded a Nobel Prize 
in Physiology and Medicine in 1903[11].  
The use of light treatment in combination with photosensitising agents was demonstrated by 
Raab in 1900[12]: in their studies, dyes were added to single-cell organisms, paramecia, in 
which, following light treatment, a loss of motion and cell death were observed. Around the 
same time a physician J. Prime, whilst treating patients for epilepsy with eosin, noticed the side 
effect of sunlight inducible dermatitis[13, 14].  Inspired by these studies, von Trappeiner 
started treating skin cancer lesions with eosin and light[11]. The need for oxygen in addition to 
drug and light was demonstrated by von Trappeiner and Jodlbauer who, in 1907, coined the 
term ‘photodynamic activation’[14, 15].   
 
In 1913, Meyer-Betz self-administered hematoporphyrin and subsequently experienced a high 
level of light sensitivity with high levels of swelling in areas exposed to sunlight which lasted 
for months,[12, 16] adding further evidence to the possibility of photochemical sensitization.  
In the decades that followed, it was noted that porphyrins show preferential tumour uptake 
compared to healthy tissue[14, 17], and that the hematoporphyrin derivative, HPD, was 
particularly tumour specific[9]. This information, coupled with the observations that photo-
sensitization of human tissue occurs with porphyrin type molecules (Figure 2a), led to their 
investigation for use in light activated therapy and ultimately to the renaissance in photo-
dynamic therapy, which started in the 1970s[16, 18, 19]. The first PS approved for clinical use 
in the treatment of cancer was Photofrin, for use in bladder cancer in 1993 (Fig. 2b). 
 
1.2 Light delivery to the photosensitiser: one vs. two photons 
As mentioned above, light activation is required to populate an excited state of the 
photosensitiser, PS*, with subsequent interaction of PS* with cellular O2 leading to the 
production of 1O2 and/or ROS[20].  If one considers a solution model whereby bimolecular 
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reaction between PS* and O2 is diffusion-limited, an estimation of the time required for the 
reaction could be made on the basis of Stern-Volmer equation: 
W0/W= 1+kdiffW0[O2], 
where W0 and W are excited state lifetimes of PS* without and with O2 respectively; and kdiff is 
the rate constant of a diffusion-limited reaction.  Assuming that kdiff in water is equal to 2x109 
M-1s-1, and that [O2] in water is 0.2mM; in order for the 50% of PS* to interact with O2, the W0 
should be of the order of 1/(kdiff[O2]), 2.5x10-6 s.  Of course, this estimate does not take into 
account the presence of O2 in the first coordination sphere of the PS*, any specific interactions, 
or any additional mechanisms of energy transport etc., and is given here purely to highlight the 
order of the timescales involved.  Given the above, molecules which readily populate a long 
lived excited state (ideally, microseconds) are sought after as photosensitisers in PDT[21].  
For the majority of molecules, the “ground”, lowest energy electronic state, is a singlet 
state (S0). Light absorption leads to initial population of a singlet excited state (S1) which can 
deactivate to the ground state in a spin-allowed process that usually occurs on the timescale of 
nanoseconds.  Singlet excited states can also undergo intersystem crossing (ISC), leading to 
population of a triplet excited state (T1). The transition T1 ĺ S0 is spin-forbidden, hence the 
lifetime of a triplet excited state is usually microseconds or longer. The long-lived triplet state 
(T1, also sometimes noted as 3PS*) can therefore be efficient in interactions with cellular 
oxygen (Figure 3).  However, as S1 ĺ T1 transition is also spin-forbidden, it is not competitive 
with the spin-allowed, fast, deactivation of S1 to S0.  In order to populate the T1 state with some 
meaningful yield, significant spin-orbit coupling (SOC) which promotes interactions of singlet 
and triplet excited state manifolds is required. Organic molecules usually have weak spin-orbit 
coupling, and consequently low yields of triplet states.  Introduction of a heavy atom, such as a 
metal centre, dramatically increases spin-orbit coupling, and promotes the population of long-
lived triplet excited states – making transition metal complexes potentially efficient PS in PDT.  
The wavelength of PS activation is one of the most important considerations in the 
selection of a PS. Absorption of light between 700 nm and 1100 nm, in the spectral range of 
relative tissue transparency is important as it allows for more diverse clinical applications, 
especially when deeper penetration into tissues is required. Traditionally, PS activation has 
been achieved by one-photon excitation with red/NIR absorbing molecules being especially 
sought after. Recently, with the advent of multiphoton lasers and light delivery technologies, 
two-photon activation in PDT is being explored as a possible future treatment modality.  In 
two-photon excitation, absorption of two photons of NIR light leads to the same excited state 
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as would normally be populated by absorption of one photon of around twice the energy. As 
such, a PS that absorbs at 350 nm can be activated by 2 x ~700 nm photons. The potential 
advantages of two-photon excitation (TPE) are that PS which absorb in the UV/Vis region of 
the spectrum can be used, that intracellular components are not affected by NIR light as they 
have negligible two-photon absorption (TPA) cross-section in this region, and that the depth of 
light penetration is much greater[22].  However, TPE imposes further requirements on the 
photosensitiser – exceptional photostability and high two-photon absorption cross-section.  
Current limitations in the development of two-photon PDT include the lack of optical 
technology for light delivery which would be sufficiently robust for clinical application, and 
the relatively small excitation volumes currently achievable in the lab. However, recent 
advances in pulsed fibre-optic lasers, which have been used for light delivery in in-vivo 
multiphoton microscopy, including that on human volunteers, create exciting possibilities of 
two-photon PDT developing into a practical approach to treatment[23]. 
 
1.3 General requirements of a PS for PDT 
While the clinical requirements for a PS can vary dependent on disease type and site, there are 
some general characteristics usually sought after [24] [21] [16] in type I and II PDT. These 
include (but are not limited to): 
(i) A long-lived electronic excited state PS* which is capable of energy or electron transfer 
to O2, leading to production of 1O2 and/or other ROS.   
(ii) Minimal cytotoxicity or biological function of the non-irradiated form of the PS and any 
products of its metabolic breakdown. This requirement differentiates PDT agents from 
other chemotherapeutics, and is key to a potentially dramatic reduction in side effects.   
(iii) Accumulation of PS in cells with, ideally, either preferential uptake, and/or higher 
retention rates in diseased tissue vs. healthy tissue.  
(iv) Targeted subcellular localisation, since reactive oxygen species will cause damage in the 
immediate vicinity of the PS.[25]   
(v) Absorption of light in the range of relative tissue transparency, 700 – 1100 nm, to 
increase penetration depth and allow for treatment of a deeper tumours. 
(vi) Chemical and photochemical stability.   
(vii)  Prompt PS clearance from the body, most importantly from the cutaneous and ocular 
tissues, to reduce the risk of long-term photosensitivity. 
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Whilst presently available clinical PS have proven beneficial in certain types of diseases, a 
number of current limitations need to be addressed in the design of next generations of PDT 
agents to widen clinical applications of the method. Absorption in the visible range which 
limits the depth of tissue penetration, is one of the general limitations of the currently approved 
PS.  Side effects present another problem - for example, the most widely used PS Photofrin, 
applied with much success in palliative lung and oesophageal cancer among others, causes a 
side effect of prolonged light sensitivity. From the implementation perspective, the cost of the 
PS[26] also plays a role.   
The need for the therapies with reduced side effects, and for therapies operating under red light, 
has sparked the design of new generations of PS beyond the originally developed heterocyclic 
ring structures, and the design of new ways of light delivery to PS, such as two-photon 
excitation, or the use of upconverting nanoparticles. 
 
1.4 Transition Metal Complexes in Photodynamic Therapy 
Following the success of cisplatin in treatments, many other TM complexes started to be 
explored as anticancer agents[27] in various treatments including PDT.  Accordingly, the last 
decade has seen dramatic expansion in the use of TM complexes as photosensitisers for 
photodynamic therapy – with the first TM PS, a Ru(II) complex known as “TLD1433” (see 
below) entering clinical trials in early 2017[28, 29].  
The reason for the growing interest in TM complexes is that they meet several essential 
requirements for a PDT photosensitiser. Such complexes typically absorb light efficiently in 
the visible region in a one-photon absorption process, whilst often possessing high two-photon 
absorption cross-section in the NIR region. The presence of a heavy atom promotes spin-orbit 
coupling leading to ultrafast (usually < 1 ps) and efficient (often close to 100%) population of 
triplet excited states[30, 31][32][33]. The high yield of triplet excited states leads to generally 
high yields of singlet oxygen generation. On the other hand, long emission lifetimes make TM 
complexes sensitive to the intracellular microenvironment – thus potentially offering combined 
“see and cure” agents. Contrary to the majority of coloured organic compounds, TM complexes 
are usually photostable (i.e., do not photobleach[33])  under prolonged one- and two-photon 
illumination, which would allow the prolonged recycling of the PS and hence an overall 
reduction in the PS dose required.  Added to these attractive photo-physical properties is the 
relative ease with which TM complexes can be synthesised, where several ligands and metal 
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centres can be combined in an almost combinatorial fashion, offering an opportunity to tune 
their photophysical properties as required.   
The present review does not embark on the impossible task of comprehensive coverage of the 
field of “transition metal complexes as photosensitisers”, but rather aims to highlight a few of 
the most recent examples in this area.  Common challenges for developing new PS include 
achieving specific targeting of subcellular structures; high water solubility; intense absorption 
in visible-NIR regions; possibility of one- and two-photon activation; and understanding of the 
mechanisms which lead to photoinduced cell death. With these challenges in mind, a number 
of complexes of Ru(II), Os(II), Ir(III), Pt, and Re(I) proposed as potential PS are discussed. 
Selected photosensitisers along with their photoactive index (PI, = LD50(dark)/LD50(light)), the 
wavelength of irradiation, the light dose used, and the mechanism of action where known, are 
summarised in Table 1.  The PI normalised by the light dose used, PI/dose, is also discussed. 
 
It is important to emphasize that the data obtained in different laboratories are extremely 
difficult to compare.  This difficulty arises due to a great diversity of the light sources used – 
continuous wave lasers vs. pulsed lasers, LEDs, broad-band sources, broad-band sources with 
filters (selecting, e.g., a 10-nm band), broadband sources with cut-off filters, etc.  
Consequently, light doses administered are equally hard to compare – it is not possible to 
estimate the amount of light absorbed by the photosensitiser in live cells, neither is it possible 
to directly compare power densities applied in different experiments. In an attempt to compare 
the results from different laboratories, a ratio of photoindex PI to the light dose is given in 
Table 1.  It is interesting to note that whilst high PIs are often reported, the ratio of PI/dose (J 
cm-2) is generally low, with only few exceptions noted in Table 1 showing PI/dose > 100.  The 
above applies to one-photon activated photosensitisers.  The ways to compare the efficiencies 
of photosensitisers activated by one-photon vs. two-photon excitation in vivo are yet to be fully 
developed.  
 
The review classifies the photosensitisers by the central metal atom, and where possible, sub-
classifies according to the ligands used, the mode of excitation, subcellular targeting strategy, 
and dual-action agents where photosensitisation is combined with another mode of treatment.  
 
2. Ruthenium (II) complexes in photodynamic therapy 
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Ru(II) complexes have been the most extensively studied transition metal complexes in relation 
to PDT. Detailed reviews by Gasser et al.[34] and Turro et al.[35] describe state of the field up 
to 2015, with recent progress reviewed in[36, 37]. Notably, the first clinical trials of a TM 
complex in PDT – a Ru(II)-based agent, TLD1433, developed in McFarland’s and Lilge’s 
laboratories (Figure 4)[28, 29, 38] for use in non-muscle-invasive bladder cancer with 
intravesical application, started in early 2017.   
 
2.1.Ru(II) diimine complexes in two-photon activation 
Since current clinically approved PS possess low two-photon absorption cross-sections, new 
PS with high TPA are required to realise what could potentially be a powerful new approach in 
PDT. The high two-photon absorption cross-section is often associated with the presence of an 
extended conjugated system. Accordingly, a number of Ru(II) complexes with extended 
organic ligands have been investigated for use as PS under two-photon excitation (TPE PS). 
Chao et al. reported a series of four mitochondria targeting Ru(II) polypyridyl complexes as 
potential TPE PS (Figure 4)[39] 1-4 which have strong absorption at around 460 nm due to 
MLCT transitions, low dark toxicity (LD50  > 100 µM), and high yields of 1O2 production (ĭǻ 
= 0.74 – 0.81). All four compounds partially localise to mitochondria in HeLa cells (64.8% - 
70.1 % by ICP MS), with 4 showing a higher affinity of 85.3 % by Pearson’s correlation 
coefficient of R = 0.88 against MitoTracker Green. The addition of -P(Ph)3 group increased the 
TPA cross-section in the region 800 nm – 830 nm, with the values of 124, 155, 170 and 198 
GM for 1- 4 respectively.  Light-induced PS activity in cell monolayers under CW light (450 
nm, 20 mW cm-2, 10 min) occurred with a PI of >28 for 4. Photosensitization in multicellular 
spheroids was shown under CW activation and under multiphoton activation (Ti:Sapp laser, 
800 – 830 nm, 100 mW, 80 MHz, 100 fs, 3 min). A high PI of >52 for 4 was observed under 
multiphoton activation compared to CW activation, showing the potential of 4 for TPE PDT.   
Pursuing the aim to reduce dark toxicity, a series of Ru(II) complexes 5 – 7 based on a 
[Ru(bpy)3]2+ core was designed by Gasser and Chao (Figure 4)[40] to avoid localisation to the 
nucleus and mitochondria. The compounds carry high positive charge (8+) and tertiary 
ammonium groups in order to increase binding affinity of the complexes to negatively charged 
cell membranes and induce cellular internalisation through an engulfing mechanism. This 
strategy has proved successful:  compounds 5 -7 localised to the lysosomes in HeLa cells 
(confirmed by ICP-MS, 5 has a correlation coefficient of 0.85 with LysoTracker Green); the 
cellular uptake pathway was energy dependent endocytosis.  ĭǻ of 0.92 – 0.99 in methanol and 
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0.49 – 0.67 in D2O, and a virtual lack of dark toxicity (LD50 > 300 µM) further supported the 
potential of 5 - 7 for PDT.  Continuous irradiation of cells incubated with 5 - 7 with 450 nm (10 
J cm-2) light led to PS activity with a maximum PI for the series being 313 (for 5); the mode of 
cell death was determined to be necrosis with spill of the cytoplasm into the extracellular 
matrix observed post light treatment. The introduction of pendant ammonium groups increased 
the TPA cross-sections of 5 - 7 to 185 – 250 GM compared to 66 GM for the [Ru(bpy)3]2+ core, 
which enabled TPE induced photosensitisation in multicellular spheroids, leading to cell killing 
at low light doses (800 nm, 10 J cm-2). High light-induced activity and exceptionally low dark 
toxicity make Ru(II) complex 5 a highly promising candidate for two-photon activated 
photosensitisation of PDT.   
Ru(II) complexes of a well-known intercalating ligand dppz, [Ru(phen)2dppz]2+, with 
various functional groups on the dppz have also been explored for one- and two-photon 
activated PDT (8 and 9, Figure 4).[41] The one-photon absorption spectra of 8 and 9 show 
MLCT transitions in the range 400-500 nm, typical for Ru(II) complexes; the TPA cross-
section values were 145 and 93 GM, and ĭǻ values of 0.75 and 0.54 for 8 and 9 respectively. 
Compound 8 had more suitable properties than 9 for photosensitisation: 8 was stable in human 
plasma whilst only 19% of 9 survived a 48-hour incubation, and 8 accumulated in cytoplasm 
and nucleus whilst 9 had high affinity to membrane binding.  Accordingly, multicellular 
tumour spheroids were stained throughout with 8, while 9 was only able to penetrate the outer 
layer. The increase in cellular uptake of 8 vs. 9 was accompanied by the higher PS effect of 8 
resulting in a higher, though still modest, value of the PI of 11.7 for 8 vs. 5.9 for 9.  
2.2  Dual action Ru(II) photosensitisers 
One emerging avenue of research is to design photosensitisers which have an additional 
therapeutic effect, a “dual agent”.  In pursuit of such combined therapies, Ru(II) complexes in 
conjunction with single-walled carbon nanotubes (SWCN) have been explored for photo-
thermal therapy (10 and 11, Figure 5)[42] as carbon nanotubes are known to convert NIR light 
(in this case, 808 nm, 0.25 W cm-2) to heat.  Carbon nanotubes acted both as photo-thermal 
therapy agents, and as a delivery vehicle of the Ru(II) complexes. Both 10 and 11 possess high 
two photon absorption cross-sections (494 GM and 428 GM respectively), and considerable 
yield of 1O2 upon excitation with blue light (405 nm, ȍǼ = 0.30 – 0.35) in D2O as determined 
by both a direct and indirect method; a fluorescent 1O2 assay (indirect method) showed 1O2 
production in HeLa cells upon TPE (808 nm, 0.25 W cm-2) with 10 and 11. The photothermal 
conversion efficiency of the SWCN loaded with ruthenium complexes was found to be 40%, 
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higher than that of the tubes alone, and led to temperature increases of 36-38 oC said to be 
sufficient for cancer photo-thermal therapy. Alongside this temperature increase, Ru(II) 
complexes were released upon excitation (808 nm, 0.25 W cm-2), and then acted as TPE PS 
under 808 nm excitation. The release of 10 and 11 from the nanotubes in cells was shown by 
multiphoton imaging under conditions when only free 10 and 11 are luminescent.  Upon initial 
imaging of SWCN/Ru(II) incubated cells, no emission is observed; however, following 
irradiation with 808 nm light, red emission was detected in the lysosomes.  The lysosomial 
localisation (confirmed by co-localisation with Lysotracker green), indicated endocytotic 
uptake of the 10- and 11-loaded carbon nanotubes. The carbon nanotubes alone, Ru(II) 
complexes alone, and loaded nanotubes showed limited dark toxicity (up to 200 µg/mL). The 
complexes and carbon nanotube alone caused photo-activated cell death, but the combined 
treatment led to dramatic reduction in cell viability. The results obtained in cell lines were also 
confirmed in multicellular spheroids and an in vivo mouse model.  This study was the first 
example of combined photo-thermal therapy with transition metal complexes and TPE PDT, 
the idea that light of the same wavelength, 808 nm, causes both a photo-triggered release of the 
PS and its two-photon activation is particularly elegant.   
 
Many Ru(II) complexes have been reported to induce DNA damage under irradiation.  Gasser, 
Ferrari et al. explored in detail how a nuclear-localised, DNA binding molecule can be used for 
PDT using an example of a new Ru(II) polypyridyl complex (Figure 6)[43]. It was shown that 
12 generates 1O2, causes photoinduced DNA damage with UV-A irradiation (350 nm 2.58 J 
cm-2)[44] and shows a dose dependant increase in photoinduced nicks in plasmid DNA. 
Through LC-MS it was shown that guanoside can be photooxidised by 12 indicating a likely 
source of DNA photodamage. Modest PS activity was observed in all cell lines tested with low 
light dose (UV-A, 1.29 J cm-2). Nuclear localisation of 12 was confirmed in a variety of cell 
lines (HeLa, U2OS, MCF7 and CAL33 cancer cell lines) with ICP-MS indicating 55% nuclear 
accumulation in U2OS cells. Both COMET and pulse-field gel electrophoresis indicated 
intracellular photo-induced DNA double strand breaks with 12 under UV-A irradiation. 
Importantly, cell cycle arrest studies allowed the authors to confirm guanine oxidation taking 
place in cells. It was determined that severe DNA damage is the likely trigger of cell death; the 
3.6-fold increase in PS activity in mitotic cells compared to non-synchronised cells is ascribed 
to less efficient photosensitisation in condensed DNA.  
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2.3. Examples of Ru(II) Photosensitisers other than Ru(II) diimine complexes  
Whilst Ru(II) complexes bearing exclusively polypyrydyl ligands are most commonly 
investigated, other Ru(II)-sensitisers have started being explored as well.  A few examples of 
such Ru(II)-based potential PS are given in this section – namely, complexes with 
cyclometallating ligands, macrocycles, and protein conjugates.  
 
Ru(II) complexes with cyclometallating ligands, [Ru(NN)2(C^N)]+, are an example of such 
potential photosensitisers.  McFarland et al. investigated the effect of expansion of the ȧ-
system of cyclometallating ligands of Ru(II) complexes (13 – 20, Figure 6)[45] on the PS 
properties of such compounds. The expansion of C^N ligands in compounds 13 – 16 was 
shown to drastically alter the interaction of the compounds with cells.  13 – 15 showed high 
levels of dark toxicity with limited light activation, whilst 16 can be considered non-toxic in 
the dark (LD50 > 300 µM) whilst exhibiting high levels of PS activity (PI >1400 in SK-MEL-
28 cells) albeit at high light dose (visible light, 100 J cm-2). This high PS activity occurs despite 
the very low ȍǼ of 0.0056, whilst O2- was suggested to be the ROS formed. 
 
A self-assembled metallomacrocycle (21), alongside its mononuclear building block (22), was 
shown to induce photoactivated killing of cancer cells (Figure 7)[46]. ȍǼ values of 0.54 and 
0.75 were found for 22 and 21 respectively, and oxygen depended photo-cleavage of DNA was 
shown with supercoiled plasmid DNA. Both compounds showed photo-induced toxicity with 
the PI of 22 (206, 48 J cm-2) being somewhat higher than that of 21.  
 
A HSA protein-Ru(II) conjugate was designed as a mitochondrial targeting PS (Figure 7)[47], 
where the blood plasma protein HSA was chosen with the aim of producing a treatment for 
acute myeloid leukaemia, and triphenylphosphine (TPP) groups were introduced to achieve 
mitochondrial targeting. Conjugation of the Ru(II) complex to HSA had no effect on its light 
absorption characteristics, but induced a 8-fold increase in the yield of photo-induced 1O2 
production (Ȣexc 470 nm) compared to the unconjugated Ru(II)-complex. Clear localisation to 
the mitochondria was observed in HeLa cells, with a relatively high PI of 220 (Ȣexc 470 nm, 
~6 J cm-2) when considering the protein concentration and an estimated 10 Ru(II) complexes 
per protein. An analogue conjugate without the mitochondria targeting TPP groups was 
somewhat less photosensitising (PI = 75) indicating the importance of subcellular localisation. 
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The two-photon absorption cross-section of the conjugate was 5-fold greater than that of the 
Ru(II) complex alone, making TPE PDT a potential future avenue for protein-PS conjugates.   
 
3. Iridium(III) complexes as photosensitisers 
The use of Ir(III) complexes for PDT is in it’s infancy.[48] Multiple papers have reported 
cyclometalated Ir(III) complexes as efficient photosensitisers of 1O2 [48-51] [52] and as 
cellular imaging agents.[53-61] The emission characteristics of Ir(III) complexes are dependent 
on the environment, indicating their potential use as pH [62] and hypoxia[63] sensing 
agents[61] as well as DNA binding agents[64].   
 
The cellular uptake of Ir(III) complexes was demonstrated in 2008 with the example of two 
cationic complexes, a green emitter [Ir(dfpy)2(bpy)]+PF6í (25) and a red emitter 
[Ir(dfpy)2(quqo)]+PF6í (26) [dfpy = 2-(2,4-difluorophenyl)pyridine] (Figure 8)[65] which were 
seen to accumulate in the cytoplasm of cells. The high photostability of the compounds in the 
cellular environment in comparison with the ubiquitous nucleic acid stain DAPI make them 
promising as imaging agents. The compounds caused limited reduction in cell viability at 
concentrations up to 100 µM, and were therefore deemed non-toxic.   
 
Following this first example, numerous Ir(III) compounds were investigated as imaging 
agents[33, 54, 57, 66-68]. Of particular note is a paper by Li et al. in 2010 demonstrating the 
ease by which colour tuning from blue to NIR [56] could be achieved in a series of six cationic 
complexes, [Ir(dfpy)2(N
ҍN)]+ (27í31; dfpy =2-(2,4-difluorophenyl)pyridine, NҍN = py, bpy, 
pyp, bq or quqo) and [Ir(piq)2(quq)]+PF6í 32 (piq = 2-phenylisoquinoline), Figure 8. The 
difference in the emission properties were attributed to different contributions from 3MLCT 
and 3LC to the emissive state. The cellular uptake of the compounds with cytoplasmic 
localisation was shown by confocal microscopy.  Limited dark cytotoxicity up to 100 µM in all 
compounds was shown following 24 hour incubations of MCF-7 and HCT-8 cells.  
 
3.1. Dual action Ir(III) Photosensitisers 
The first example of photosensitized killing of live cells by Ir(III) compounds (39 – 41), Figure 
9)[69] was reported in 2012. The compounds, Ir(III) metallo-pyridocarbazoles, were designed 
as protein kinase inhibitors to be used as dual antiangiogenic and photosensitizing agents. 
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Compounds 39 – 41 were phototoxic at 1 µM under light of > 450 nm, 41b caused significant 
apoptosis, and demonstrated a PI of 34.35. The mechanism of action was suggested to be type 
III with photo-induced ligand substitution by cellular Cl- leading to photo-induced labilization 
of the selenocyanate ligand (-SeCN). However, the separately prepared proposed photo-
substitution product, 41a, showed no dark cytotoxicity, and it therefore remains unclear if the 
selenocyanate ligand would cause the apoptotic death of the cells.  The compound 41b retains 
antiangiogenic action, whilst its methylated derivative shows no protein kinase inhibition.  In 
human umbilical vein endothelial cells (HUVEC) which highly express vascular endothelial 
growth factor receptor kinases (VEGFR), known to be inhibited by 41b[70] but not the 
methylated analogue, 24 hour incubation with 41b (5 µM) caused apoptotic cell death whilst 
the methylated analogue did not. Photo-induced toxicity to HeLa cells was demonstrated by 
41b, showing its potential as a dual therapeutic agent.   
 
Another example of dual-action agents is a series of Ir(III) complexes Ir(C^N)2L](PF6) (L = 
N1-hydroxy-N8-(1,10-phenanthrolin-5-yl)octanediamide) 42 - 45, Figure 10,[71] designed to 
combine histone deacetylase (HDAC) inhibition with photosensitization. HDACs regulate the 
histone modification by catalysing the removal of acetyl groups from histones, in this way they 
can alter gene expression patterns often associated with cancer,[71] thus HDCAs are indicated 
as anticancer drugs with at least two approved by the FDA[72]. One such HDAC is  
suberanilohydroxamic acid, SAHA. SAHA was incorporated into a phenanthroline ligand for 
all compounds 42 – 45. The ȍǼ values for 42 – 45 (Ȝexc 425 nm) range from 0.21 – 0.75 in 
ascending order 44<43<42<45. All compounds localised to the cytoplasm, and showed 
phototoxicity with UV (Ȣexc 365 nm, 3.6 J cm-2) and blue excitation (Ȣexc 425 nm, 7.2 J cm-2) 
resulting in PIs in the range 2.7 – 18.9. All compounds retained HDAC inhibitory function, 
with 43 showing a higher inhibitory effect than SAHA. Compound 42 exhibited the strongest 
photodynamic response in HeLa cells under 365 nm irradiation. Histone H3 acetylation levels, 
indicative of HDAC inhibition, were higher with 42 and light in comparison with 42 in the 
dark, indicating that HDAC inhibition was enhanced upon irradiation. Apoptosis levels 
increased in a dose dependent manner with 42 in the dark whilst light treatment greatly 
increased the levels as demonstrated by Annexin-V binding and caspase-3/7 activation. 
Mirroring these results, cellular ROS concentration increased and mitochondrial membrane 
potential (MMP) decreased in a dose dependent manner in the dark, whilst light treatment 
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caused a 5-fold increase in ROS levels and a marked drop in MMP. This study demonstrated 
the promise of HDAC inhibitors incorporated into Ir(III) photosensitiers as dual-action drugs.   
 
3.2.Two-photon activated Ir(III) Photosensitisers 
The first example of TPE PS with Ir(III) complexes was demonstrated using a compound 
[Ir(ppy)2(phen)]Cl, 46  (Figure 11, ĭǻ = 0.036 in H2O).[73]. 24-hour incubation of live cells 
with 46 (up to 10 µM) did not result in visible differences in cell morphology.  However, when 
incubation was followed by irradiation with 800 nm light (30 min, 2.4 mW, 80 MHz), an 
assessment by eye 150 min later led to the clear, albeit qualitative, conclusion that the 
compound was phototoxic to cells.   
The next report of Ir(III) TPE killing of cells used a cyclometallated fluorenyl Ir(III) complex 
47 (Figure 11)[74], analogous to a Ru(II) compound previously reported by the same 
group[75]. The close match of one and two-photon excitation spectra indicated that the same 
excited states are accessed in both cases, with TPA up to 80 GM in the range 700 – 800 nm. 
The TPE cell damage effect of the compound was shown in a G6 Glioma cell line, change in 
morphology of the cells was used to determine cell death. The compound (1 µM) and light 
(740 nm, 220 J cm-2) caused morphological change while light alone did not.  
In mid-2016, Lim et al. reported a series of Ir(III) compounds as PS (48 – 51, Figure 11),[76] 
these showed some phototoxicity under one-photon excitation (PI 5.64, albeit with a low light 
dose - sunlight, estimated as 1 J cm-2). Complex 50 was also phototoxic under two-photon 
excitation; demonstrated in a single cell at high Ir(III) concentrations (20 µM). The cell death 
mechanism was confirmed to involve the ROS and 1O2 production in cells under these 
conditions.   
Recently, our groups in collaboration with others, demonstrated that representative of 
[Ir(N^C)2(N^N)]+ family of cyclometallated Ir(III) complexes 52 and 53 (Figure 11)[77] are 
efficient PS under one photon activation. Furthermore, compound 52 proved to be efficient in 
two-photon activated cell killing. This study was the first example of TPE PS demonstrated on 
cell monolayers with an Ir(III) complex. The compounds have appreciable ȍǼ of 0.42 and 
0.40 for 52 and 53 respectively. Rapid uptake in HeLa cells was seen for both compounds. 
Importantly, 52 was virtually non-toxic in the dark up to 100 µM concentration (highest 
concentration tested) while its N-methylated analogue 53 was somewhat more toxic with an 
LD50 of 6.5 µM. The localisation of 52 changed over time, from mitochondrial (< 4 hrs 
incubation) to lysosomal at the 24-hr time point, potentially indicating the trafficking of 52 out 
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of cells. Compound 52 was shown to be an efficient PS under low dose violet light (3.6 J cm-2, 
405 nm) in a number of cell lines, with a maximum PI of  >555 demonstrated in U2OS cells 
(osteosarcoma). Apoptosis and ROS production in cells post light treatment were confirmed in 
HeLa cells. The potential use of the compound in TPE PDT is demonstrated by a relatively 
high Ȫ2 of 112 GM at 760 nm and TPE mediated PS of cells was demonstrated on HeLa 
monolayers by Annexin V and PI staining.    
 
The studies above were concerned with molecular photosensitisers, or their covalent conjugates 
to specific functional groups. A different approach was reported by Chao et al. who designed a 
series of Ir(III) complexes 54 – 56, that showed aggregation induced emission (AIE) and 
associated TPE PS activity (Figure 12)[78]. The hypothesis was that the compounds are non-
emissive at low concentrations due to quenching of the excited state by the rotation of the 
fluorogen group in solution, whilst at increased concentration aggregation prevents the rotation, 
inhibits this route of excited state quenching, and restores the emission. For 54 – 56 only weak 
emission was observed (yield 0.001) in DMSO solution, this increased upon addition of water 
and reached maximum intensity at 90% (v/v) water/DMSO ratio (yield 0.044). Aggregation of 
the complexes in the 90/10 water/DMSO solution was confirmed by dynamic light scattering, 
indicating nanoaggregates of 88.99 – 250.09 nm.  ȍǼ were also reported to be highest at 90/10 
water/DMSO; 54 demonstrated a greater consumption rate of DPBF (1O2 scavenger) than the 
standard used (H2TPP, ȍǼ = 0.70 in toluene). 54 was found to have a high TPA of 214 GM at 
730 nm. Compound 54 which is more lipophilic than 55 and 56 (logPo/w = 1.42, 1.06 and 0.77 
respectively) was shown by ICP-MS to accumulate in the mitochondria (>80 % of accumulated 
compound) of HeLa and L02 (human hepatic) cells. Lower uptake was observed in the normal 
cell line and was ascribed to the higher membrane potential of cancer cells. 54 was shown to 
enter cells via an endocytic pathway. The dark and light (405 nm, 40 mW cm-2, 12 J cm-2) 
toxicity of the compounds in HeLa and L02 cell lines showed similar dark toxicities (dark-
LD50 = 29.2 – 30.3 µM and 32.2 – 34.0 µM for HeLa and L02 respectively) but higher light 
toxicity in HeLa cells leading to higher PI of 54 in HeLa cells (PI = 75 and 14 for HeLa and 
L02 cells respectively). A number of measurements indicated that the mitochondrial oxidative 
phosphorylation pathway is impaired post PS treatment, which, along with the observed 
activation of caspase-3/7 post light treatment likely indicates apoptotic cell death. The ROS 
production in cells and PS activity with TPE (730 nm, 0.88 W cm-2, 50 s, 12 J cm-2) shown for 
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54 indicate the potential use of the compounds for TPE PDT. This was supported by the studies 
of multicellular spheroids (light-LD50 = 0.35 µM, PI = 100).   
 
In early 2017, a series of organelle specific Ir(III) terpyridine complexes for TPE PDT, (57-61, 
Figure 12)[79] with one-photon absorption in the range 350 nm to 520 nm, and maximum Ȫ2 
values of 60 – 110 GM at around 800 nm were reported. Compound 57 localized to the 
nucleus, while 58 - 61 localized to the mitochondria in HepG2 (human liver cancer) cells. 
Inhibition assays showed that 57 entered cells through microtubule-dependent endocytosis, 
whilst the uptake of 58, used as a representative of all non-nuclear PS, was partially inhibited 
by a number of inhibitors, indicating a mixed mode of uptake. By analysis of cell morphology, 
and annexin V / propidium iodide staining, it was determined that the nuclear localizing 57 
caused drastic morphology changes in cells following TPE (800 nm) while, despite their 
similar 1O2 sensitizing capabilities, the mitochondrial targeting 58 did not. TEM imaging of 
cells treated with 57 and TPE (800 nm, 30 s, 30 min intervals, 2 hrs) showed cells containing 
multiple vacuoles, indicative of induction of apoptosis. DNA cleavage post light treatment was 
shown in supercoiled DNA incubated with 57.  
 
3.3. Subcellular targeting with Ir(III) photosensitisers 
As with all PS, disease-specific uptake and intracellular targeting are aims of molecular design 
of Ir(III) PS. 
 
Zhang et al. reported two fructose containing Ir(III) polypyridine complexes alongside their 
fructose free analogues in 2013 (Figure 13)[80]. This work exploits the fact that highly prolific 
cells require more energy and hence overexpress glucose transporters (GLUTs). Therefore, 
incorporation of sugar molecules may allow for increased uptake in neoplastic cells.  Whilst an 
exciting prospect, the results with these particular complexes indicated that the fructose 
containing compounds showed lower cellular uptake than their fructose-free counterparts – the 
result was ascribed to the increased hydrophilicity imparted by the sugar molecule, as cellular 
uptake of TM complexes is often dependent on the level of lipophilicity of the complex[61, 81, 
82]. Addition of unmodified fructose reduced the uptake of the fructose containing 64, whilst 
65 uptake was unaffected, indicating regulation of uptake of 65 by membrane bound fructose 
transporters. The compounds showed mitochondrial localisation, but displayed high dark 
toxicities and therefore light toxicities were not explored further.   
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Lo et al. developed this approach of targeted accumulation further. In one example, a series of 
compounds in which ligands were equipped with either ester groups, 66 and 67, or carboxylate 
groups, 68 and 69, displayed significant differences in cellular internalization (Figure 14)[83]. 
The complexes with ester groups were taken up by the cells readily via an energy dependent 
pathway and localised in mitochondria and endosomes, whilst the carboxylate compounds were 
not easily taken up by cells – the effect was ascribed to limited membrane permeability as 
confirmed by emission imaging which detected the compounds at the cell membrane. 
Compounds 66, 68 and 69 showed low levels of dark toxicity (LD50 > 200 µM) whilst 67 was 
somewhat more toxic (LD50 = 8.6 ± 0.1 µM). The carboxylate compounds showed no increase 
in toxicity upon light treatment, whilst both ester compounds demonstrated increased light 
toxicity with PI values of 11.56 and 17.2 for 66 and 67 respectively. The light dose is quoted as 
‘irradiated at 365 nm with a 6 W UV-A lamp (Spectroline, USA) for 1 h’.   
 
Two related Ir(III) complexes, 70 and 71 (Figure 15), which share the same central 
cyclometallated Ir(III) resulting in similar photophysical properties (ȍǼ 0.17 and 0.21 for 70 
and 71 respectively), showed different organelle specific subcellular localisation, mitochondrial 
and lysosomal one, resp. [84]. The intracellular localisation was confirmed by co-localisation 
with mitotracker green and LysoGreen for 70 and 71 respectively (Pearson’s correlation 
coefficients 0.85 and 0.91, respectively). Cellular uptake studies indicated an energy-dependent 
endocytosis pathway for the uptake. Hypoxic incubation with 70 and 71 altered the decrease in 
O2 levels in the culture media compared to untreated cells. In complex treated cells an 18 % 
and 29% decrease in oxygen was observed after 15 min in the hypoxic environment in 
comparison a 44 % decrease was observed in untreated cells. This indicated that cellular 
respiration was decreased when cells were treated with either 70 or 71 with a less marked 
decrease in O2 for the mitochondrial targeting 70 (18 % vs 29 %). Both compounds had low 
dark cytotoxicity in HeLa cells, however, under hypoxic conditions the mitochondrial localized 
PS had somewhat higher phototoxic activity then the lysosomal PS. The authors attributed this 
difference to the advantages of mitochondrial localisation in hypoxic conditions, although it 
could also be due to a higher effect of the mitochondria-localised PS.   
 
3.4. pH sensitive Ir(III) photosensitisers 
A number of pH sensitive Ir(III) complexes have been proposed as PS due to the potential of 
preferential localisation. A representative example, a pH-sensitive Ir(III) complex fac-
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Ir(deatpy)3 (73, deatpy = 2-(5’-N,N-diethylamino-4’-tolyl) pyridine, Figure 15),[85] with a pKa 
of 7, shows negligible emission at pH 7.4 but strong emission (Ȣem 497 nm) at pH <7 
attributed to a reversible formation of its protonated form, 72. In HeLa-S3 cells 72 co-localised 
with LysoTracker indicating lysosomal localization, with passive uptake mechanism confirmed 
by uptake studies at 4 °C. 72 was shown to result in production of 1O2 upon excitation with 366 
nm. Following prolonged excitation (30 min) at both 366 nm and 470 nm, cells incubated with 
10 µM solution of 72 were shown to exhibit cell membrane swelling indicating cell death. Cell 
death at 366 nm was confirmed, and determined to be mainly necrotic, by Annexin and 
Propidium Iodide staining. Several related pH-responsive compounds were reported in 
2013,[86] and later expanded to a series of pH-sensitive Ir(III) complexes which showed 
photoinduced toxicity[87].   
 
A series of pH-responsive Ir(III) complexes showing clear lysosomal staining and a high PI of 
>833 (although at the high light dose of 36 J cm-2 ) have been reported (64 – 77, Figure 
15)[88]. One of the compounds was shown to have selectivity for cancer cells although, the 
authors state that the need to excite at 425 nm would limit its clinical application.   
 
3.5.Red/NIR activated Ir(III) photosensitisers 
A possible approach to efficient PDT under red/NIR light is to create a hybrid organic-
inorganic agent, which would allow one to utilise the broad visible/NIR absorption of the 
organic fluorophore whilst retaining the ISC offered by the TM centre.  
In realisation of this idea, four Ir(III) complexes were investigated, here bulky organic 
fluorophore mono/di-styryl BODIPY derivatives were attached to the coordination centre via 
an acetylide linker (78 – 81, Figure 16)[89]. This design allows ȧ-conjugation across the 
molecule, so that following absorption of red light by the fluorophore, the resulting singlet 
excited state undergoes efficient ISC to the desired triplet excited states. Whilst the complex 
without BODIPY is characterised by relatively weak visible light absorption (Ȝ 1.51 x 104 M-1 
cm-1 at 385 nm) and no NIR absorption, the BODIPY-Ir conjugates had strong absorption in 
the red region: 78 (H 1.14 x 105 M-1 cm-1 at 606 nm), 79 (H8.96 x 104 M-1 cm-1 at 644 nm), 80 
(H 9.89 x 104 M-1 cm-1 at 644 nm) and 81 (H 7.98 x 104 M-1 cm-1 at 729 nm). Fluorescence of 78 
- 81 was weaker than in their non-coordinated BODIPY ligand counterparts indicating some 
interaction with the metal centre. Transient absorption studies established that the long-lived 
triplet excited states were localized on the styryl-BODIPY ligand rather than the coordination 
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centre; the lifetimes of the triplet excited states were determined to be in the range ~156 Ps to 
31.4 Ps, where the decrease in the lifetime correlates with the decrease in the excited state 
energy. )' varied dramatically between the compounds, from 0.53, 0.83 to 0.06 and 0.02 for 
78 - 81, respectively. 78 – 80 were shown by emission microscopy to accumulate in lung 
cancer cells, whilst 81 - the compound with the lowest yield of 1O2 production, the shortest 
emission lifetime, but the longest absorption wavelength of >700 nm - did not permeate into 
cells. In the cell lines 1121 and LLC 78 was shown to have PIs of 3.8 and 1.32 and 79 PI s of 
2.17 and 1.59 respectively. Whilst modest, and difficult to compare with other studies as the 
light doses were not specified, these PI values are rather remarkable for TM complexes with 
excitation at 635 nm.   
 
Late 2016 saw the publication by McFarland, Sun et al. of a series of six Ir(III) complexes (82 
– 87, Figure 17)[90]. The compounds were designed using the idea that extended diimine ʌ-
conjugation can increase the triplet state lifetimes in complexes containing diimine ligands 
with the 3IL state slightly lower in energy than the 3MLCT state for the complex [91]. This idea 
was previously shown to increase photosensitising activity of Ru(II) complexes,[92] as well as 
increasing the lifetime of charge-transfer triplet excited states in some cases [93, 94]. 
Accordingly, a series of complexes with extended S-conjugation of the diimine ligand (82 – 
84) and the cyclometallating ligand (85 – 87) were designed. Complexes 85 – 87 had 
absorption band red shifted relative to 82 – 84. The extension of the diimine S-conjugated 
system shown to affect the ground state absorption but not the triplet state emission energy, 
while extension of the S-conjugated system in the cyclometallaing ligand was shown to affect 
both the ground state and the emitting triplet state. The extension of the cyclometallating S-
conjugation visible absorption into the red/NIR was ascribed to a direct S0 – Tn transition via a 
3S,S*/3CT transition. The PS effects of 82 – 83 were tested in SK-MEL-28 (melanoma) and 
HL60 (leukaemia) cell lines under irradiation with broadband visible light (400-700 nm, 34.2 
mW cm-2) or red light (625 nm, 29.1 mW cm-2) at a rather high light dose for both (100 J cm-2). 
Compounds 82 – 86 were somewhat toxic in the dark to both cell lines (LD50  2.11 µM and  
4.51 µM for SK-MEL-28 and HL60 respectively) whilst 87 was significantly less toxic (LD50 = 
144 µM and 83.8 µM). All compounds had PS activity in both cell lines with greater effect 
under visible light (PI = 22 – 407 and 12 – 143 for SK-MEL-28 and HL60 respectively) 
compared to red light (PI = 1.2 – 32 and 1.5 – 16 for SK-MEL-28 and HL60 respectively). A 
mixture of subcellular localisations was observed for the compounds, with 87 showing nuclear 
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staining in adherent cells and cytosolic staining in suspension. Irradiation of light to plasmid 
DNA in the presence of 87 was not found to induce strand breaks but to aggregate or condense 
the DNA. 87 showed the greatest promise in both cell lines at each wavelength with the 
greatest PI of 407 with visible light activation in SK-MEL-28; however, the light dose 
administered was high, 100 J cm-2.  
 
3.6. Other examples of Ir(III) photosensitisers 
A series of cyclometalated Ir(III) polypyridine compounds incorporating polyethylene glycol 
(PEG) chains and their PEG free counterparts were investigated by Lo et al. (88 – 97, Figure 
18)[95]. The PEG chains were added with the aim of increasing the water solubility of the 
Ir(III) complexes and reducing the dark cytotoxicity as the addition of PEG chains is often 
linked to reduced interaction of the complexes with biological entities such as DNA and 
proteins[66, 96]. The )' for the compounds were in the range 0.24 - 0.79 (in aerated DMSO 
against the standard methylene blue) and generally increased across the series 88 < 92 and 93 < 
97. The PEG variants were found to be less lipophilic than their PEG-free counterparts, with 
ICP-MS indicating higher cellular uptake of the PEG free complexes. This is an interesting 
finding as it may indicate that PEG addition is not the best route for PS design. 90 localised to 
mitochondria (Pearson’s correlation coefficient 0.909), as expected given the cationic and 
lipophilic nature of the compound. The low dark cytotoxicity of the PEG compounds (LD50 > 
300 µM in all cases) is considerably lower than that of the PEG free compounds although this 
cumulative effect was, perhaps, to be expected due to lower cellular uptake imparted by 
incorporation of the PEG chains. The PEG containing compounds, except 92, were phototoxic 
in HeLa cells with appreciable PI values in the range of >12.9 to >88.2, although the light dose 
appears likely to be large (365 nm, 30 min with a 6 W UV-A lamp) and may need to be 
optimised to become relevant to the clinic.  
Incredibly high light toxicities (as low as LD50 0.00086 µM, PI 3488 in A549R cells) have 
been demonstrated by mitochondria targeting complexes 98 – 100 (Figure 19),[97] whilst dark 
toxicity against a number of cell lines was remarkably low, in the range LD50 1.0 µM - 17.3 
µM. This value is the highest PI of an Ir(III) compound reported. Interestingly, the PIs in HeLa 
cells were much lower (up to 49) and the light dose used was reasonably high (20 J cm-2) in the 
UV region (365 nm) which would severely limit the clinical application of the compounds. The 
lipophilicity of the compounds was found to correlate with both their uptake and 
photosensitizing efficiency of the compounds, a finding further supporting the link between 
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lipophilicity and intracellular uptake of small molecules. The compounds were shown to induce 
apoptosis by mitochondrial damage but cell cycle analysis indicated that the compounds were 
not genotoxic.   
 
Maggioni et al. reported water soluble compounds 101 and its conjugate to a poly-
(amidoamide) copolymer 102, which localised in the perinuclear region, and induced apoptosis 
under Xe lamp illumination (Figure 19)[98].  The molecules of 102 self-assembled in water 
into spherical nano-aggregates of roughly ~30 nm diameter. Compared to the polymer 
conjugate 102, compound 101 had twice as high ĭǻ, and required much shorter incubation 
times to accumulate in cells (2 hr vs. 12 hr). It was also is significantly more toxic in the dark, 
but showed higher photosensitizing activity with lower levels of necrosis. 
 
A dinuclear Ir(III) complex containing a bridging boron-dipyrromethene (BODIPY) 
chromophore and its Ru(II) analogue were reported by Draper et al. (103 and 104, Figure 
20)[99]. Both compounds absorbed strongly in the visible range (567 nm, H 105713 dm3 mol-1 
cm-1 and 570 nm, H 113317 dm3 mol-1 cm-1) for the Ir(III) and Ru(II) complexes respectively, 
showed low dark toxicity (LD50 = 300 µM), considerable light toxicity (although their light 
toxicities were not determined quantitatively), and are therefore promising PDT agents.  
 
Gasser, Chao, et al. reported Ir(III) and Ru(II) complexes bearing aromatic acid diimides as 
additional light absorbers (105 and 106, Figure 20)[100]. Both compounds were shown to 
sensitise production of 1O2 under at 420 nm irradiation through an indirect and direct detection 
method, although no signal could be measured for 105 by the direct method, perhaps due to the 
limits of the detection (detection limit )' = 0.24) with  )' = 0.29 in CH3CN by the indirect 
method. No )' was observed for either compound under excitation at 575 nm. The PS effect of 
105 and 106, and associated ligands 107 and 108, was tested in three cancer cell lines: A2780 
and A2780R, cisplatin-sensitive and cisplatin-resistant ovarian epithelial cancer cell lines and 
HeLa. The two ligands showed no PS effect whist both 105 and 106 showed photosensitization 
in all cell lines (Oexc 420 nm, 9.27 J cm-2) with 106 showing higher PI in all cells (PI up to >23 
in A2780 cells). The subcellular localisation of 105 and 106 was determined, by ICP-MS, to be 
nuclear for 105 and mainly mitochondrial for 106; it was suggested that the higher dark toxicity 
of 105 may be imparted by the nuclear localisation with DNA interaction a possible source of 
the toxicity.   
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A series of 5 mitochondrial targeting PS for PDT of the general formula [Ir(ppy)2(L)]+ where L 
is a 2,2’-bisimidazole ligand equipped with varying length alkyl chains to alter the lipophilicity 
of the compounds, have been investigated (109 – 113, Figure 20)[101]. The ȍǼ of the 
compounds were 0.17, 0.21, 0.28, 0.51 and 0.59 for 109 - 113 respectively. The octanol/water 
partition coefficients (Log Po/w) indicated increasing lipophilicty with increasing chain length; 
110 < 111 < 112 < 109 < 113 with the exception of the non-alkylated 109. All complexes were 
readily taken up by HeLa cells and localised to the mitochondria as shown by colocalisation 
with MitoTracker Red (Pearson’s correlation coefficients in the range 0.8 – 0.87) and 
confirmed by ICP-MS. Their PS activity in HeLa cells is characterised by PI, as follows: 113 
(150) > 112 (64.6) > 109 (49.7) > 111 (42.2) under irradiation at 405 nm (20 mW cm-2, 5 min, 
6 J cm-2). Importantly, the authors reported lower PI in the non-cancerous cell line LO2 
indicating a potential preferential killing of cancer cells. 113 was shown to kill cells via 
apoptosis with ROS shown to increase in HeLa cells post light treatment with loss of 
mitochondrial membrane potential indicated.   
 
4. Platinum complexes as photosensitisers  
A large number of octahedral Pt(IV) compounds have been explored as photoactivatable drugs, 
which could be photo-converted into Pt(II). These Pt(IV) complexes induce cell death via the 
non-oxygen dependent ‘Type III’ pathway and as such are deemed to work as photoactivated 
chemotherapeutics (PACT) rather than as PDT agents. A large body of work has been 
published harnessing the relative ease of interconversion between the oxidation states of 
platinum, where non-cytotoxic octahedral Pt(IV) compounds could be photochemically 
converted to cytotoxic square planar Pt(II) complexes exhibiting cisplatin-like activity. These 
compounds would circumvent the issues associated with hypoxia and PDT but may fall foul of 
cisplatin resistance. This exciting work is summarised in detail in many recent reviews, for 
example [102][103][104][105].   
Despite numerous studies indicating Pt(II) complexes as efficient singlet oxygen 
sensitizers,[48] very few platinum compounds have been shown to exhibit photosensitizing 
effects via a type I or II mechanism.  
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Having noted that previous papers had shown photosensitizing properties of porphyrin 
complexes with peripherally conjugated ruthenium complexes[106, 107], Spingler et al 
designed three tetra-platinated porphyrins (115 – 117, Figure 21) based on the naked porphyrin 
114[108]. The ȍǼ were in the range 0.54 - 0.41 for 114 - 117, respectively. Photo-induced 
action of 114 – 117 was tested in MCF-7, HeLa, A2780 and CP70, a cisplatin resistant cell line 
with low dose violet light (420 nm, 6.95 J cm-2). Incorporation of the peripheral platinum 
groups drastically increased the photosensitisation effect in HeLa cells, increasing from PI 
=17.3 for 114 to an incredibly high PI of 1210 for 117, with light induced LD50 for 115 – 117 
in the nanomolar range. Photosensitisation was also shown at a higher wavelength (575 nm, 
6.95 J cm-2) albeit to a lesser degree. Following these outstanding results 115 – 117 were tested 
in a cisplatin resistant ovarian cancer cell line, A2780, again with violet light (420 nm, 6.95 J 
cm-2) leading to remarkable PIs of 1110, 1930 and >5260 for 115, 116 and 117 respectively. 
The compounds were shown to enter the nucleus by confocal microscopy with the nuclear 
uptake of 117 confirmed by ICP-MS confirmed to be at 99.5 % (0.5 % cytoplasmic). Having 
demonstrated nuclear localization, 117 was shown to exhibit strong binding with calf thymus 
DNA (ctDNA) with an apparent binding constant calculated by competitive binding 
experiments with ethidium bromide (EB) to be Kapp = 7.5 x 106 M-1. The intercalative nature of 
the binding was confirmed by circular dichroism studies. No DNA cleavage was observed with 
117 in the dark but light treatment caused an increase in DNA damage indicating DNA as the 
likely target of the compound.   
 
In 2016, in collaboration with other groups, we reported the first example of oxygen mediated 
photosensitization of cell death by a small cyclometallated Pt(II) complex, Pt(II) 2,6-dipyrido-
4-methyl-benzenechloride (118, Figure 21)[109]. The molecule demonstrated an appreciable 
ȍǼ of 0.7 and was capable of inducing photosensitization of a number of cancer cell lines with 
low dose violet light (405 nm, 3.6 J cm-2).  The compound, previously shown to accumulate 
predominantly in the nucleus with some cytoplasmic staining[110], was shown here to bind to 
DNA by metaphase spread indicating chromosomal staining. Bimodal DNA binding was 
deemed likely due to the biexponential emission decay of the DNA-bound compound ascribed 
to a mixture of intercalation and groove binding. Competitive binding with EB confirmed at 
least partial intercalation with a binding constant calculated to be 1.19 (±0.08) 105 M-1. The 
light induced DNA damage of the compound was investigated by agarose gel electrophoresis, 
induction of single strand breaks (SSB) in plasmid DNA was found with the combination of 
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compound and light but not compound or light alone. Oxygen was also implicated as hypoxic 
conditions reduced the formation of SSB, competitive EB binding also reduced SSB formation 
indicating that the intercalated binding mode was responsible for the damage. Induction of 
SSBs in cells was confirmed by COMET assay with significantly more damage observed when 
cells were treated with compound and light versus light or compound alone. The compound 
had a PI of 8.   
Whilst the tetraplatinated porphyrin molecule showed high PS activity in a number of cell 
lines, the small cyclometallated Pt(II) molecule had relatively high levels of toxicity in the 
dark. This feature might have hindered exploration of Pt(II) complexes as photosensitisers of 
cell death in the past, as there are such limited reports of Pt(II) mediated PS of cells via a type I 
or II mechanism.   
 
5. Osmium (II) complexes as photosensitisers 
While there are reports of DNA photocleavage by Os(II) compounds[111, 112] there are very 
few reports of their PS activity in cells. The first such report, published in 2007 by Brewer et 
al, discussed two trinuclear metal complexes consisting of a central co-ordinating Rhodium 
between two metal centres, either Ru(II) or Os(II) (119 and 120, Figure 22)[113]. The design 
rationale was built on the reports of rhodium and mixed metal complexes having induced 
photo-cleavage of DNA[114], in which metal-to-metal charge-transfer (3MMCT) from the 
Os(II) or Ru(II) to the rhodium centre was considered to be responsible for the DNA cleavage. 
The irradiation of Vero cells incubated with 119 and 120 (Ȣexc > 460 nm, 4 min) led to higher 
levels of cell death relative to non-irradiated cells.   
 
In 2016, two polyazine complexes, of Os(II) and Ru(II), were reported (121 and 122, Figure 
22)[115]. The absorption spectrum of the Os(II) complex, 122, is slightly red shifted compared 
to the Ru(II) complex (ǼȢ = 20 nm) and shows greater absorption (24x higher) in the red (Ȣ 
650 nm, 3MLCT absorbance) attributed to the higher spin-orbit coupling from the heavier 
metal. The Os complexes demonstrated modest PIs of 9.86 and 5.8 under 470 nm and 625 nm 
excitation, respectively, in F98 (rat malignant glioma cells) – this is the first example of 
transition metal PS in glioma cells.   
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In April 2017 McFarland, Lilge, Mandel, et al. reported three Os(II) complexes as PS, these 
were tested in diverse cell lines and in mice (123 – 125, Figure 23)[29]. In order to have 
several charge-transfer transitions involving different ligands and achieve pan-chromatic 
absorption to harness as much light as possible, the Os(II) complexes bore two different 
diimine ligands, bipyridine and 2,2’-biquinoline (biq). All three compounds 123, 124, and 125 
showed some absorption across the region 200 nm – 1000 nm with ligand centred transitions in 
the UV, a transition around 550 nm associated with MLCT from the Os(II) to the non-biq 
ligand and the broad absorption into the NIR associated with the MLCT to the biq ligand, with 
additional contributions from the spin –forbidden singlet-triplet transitions induced by high 
SOC of the Os center. Important in the context of antitumor treatments is the low ȍǼ of 0.04 
for 123 and 124 with no 1O2 detected for 125, the finding is consistent with the lack of O2 
quenching of photoluminescence of the compounds and indicates an O2 independent pathway 
for the PS cell killing.  The three compounds showed low dark toxicities in both U87 (human 
glioblastoma) and HT1276 (human bladder cancer) cell lines (LD50 = 416 µM – 744 µM) with 
modest PIs with red light excitation (PI = 3.3 – 9.6) at relatively high dose (625 nm, 90 J cm-2) 
and with one-photon NIR light (PI = 2.6 – 12) at another high light dose (808 nm, 600 J cm-2). 
Whilst these light doses are extremely high it is worth noting that this excitation is in the NIR 
using non-multiphoton lasers. The compounds were tested in mice and showed variability in 
their maximum tolerated doses (MTD) (‘defined as the highest dose (mg kg-1) that does not 
cause an animal distress’). The MTD for 123 was 1.25 mg kg-1 (below the acceptably limit for 
in vivo studies). For 125 the MTD was 6.25 mg kg-1, and for 124 the MTD was high with 
tolerability at 47.0 mg kg-1. 125 was therefore tested in mice with a subcutaneous colon tumour 
model. PS alone (at half the MTD) and light alone showed no significant increase in survival 
whilst PS and 192 J cm-2 red light slowed tumour growth and increased survival significantly 
(P<0.01) compared to light only but not compared to PS only controls. A higher light dose (266 
J cm-2) combined with 125 led to complete tumour regression in most animals. The PDT effect 
was also tested in the NIR (808 nm, 600 J cm-2) and caused significant survival gains compared 
to PS and light alone.   
 
The lack of Os(II) complexes reported for PDT is somewhat surprising considering the relative 
wealth of Ru(II) complexes presented in the literature. One possible explanation is the usually 
shorter excited state lifetime of Os(II) complexes[116, 117] due to energy gap law – however, 
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recent results clearly show the potential of Os(II) complexes and assemblies thereof to act as 
photosensitisers for photoinduced cell death.  
6. Rhenium(I) complexes as photosensitisers 
The first report of photosensitizing activity of a Re(I) compound in 2013 described a series of 
three photosensitizing compounds 126a – 126c alongside a nontoxic luminescent probe 127 
(126 – 127, Figure 24)[118]. The authors observed a surprising result that replacing the 2,2’-
bipyridine ligand of the Re(I) complex 127 with 2-(2’-pyridly)indolato ligand (and its 
derivatives) led to the loss of luminescence of the complex whist leading to light-induced 
anticancer activity. Complex 126a had a PI of 1000 in HeLa cells, although the light dose was 
incredibly high (>505 nm, 60 min, 29.2 mW cm-2 (giving 105.12 J cm-2)) with cell death 
determined to be via apoptosis. Whilst 126a showed light induced toxicity at longer 
wavelengths ( 505 nm) both 126b and 126c required shorter wavelengths for activation ( 
415 nm) and 127 showed no phototoxicity even under UV irradiation ( 330 nm). Cell 
blebbing consistent with cell killing was observed by emission microscopy in cells incubated 
with 1 (1 µM) and a dose of light (LED light source) as high as 7 W, for 15 min. The efficiency 
of light-induced cell death mirrored the efficiency of singlet oxygen sensitisation by 126a – 
126c at various wavelengths ( 505 nm,  415 nm and  330 nm), implicating 1O2 as the toxic 
agent produced.  This hypothesis was further supported by the reduction in the efficiency of 
light-induced cell killing in cells co-incubated with 126a and the anti-oxidant D-tocopherol 
(vitamin E). The PS ability of 126a was also confirmed in melanoma spheroids.  Although the 
extremely high light doses required would make developments of these specific compounds 
impractical, the work has clearly demonstrated the potential of the Re(I) complexes as 
photosensitisers for light-induced cell killing.   
 
Specific intracellular targeting with Re(I) complexes was achieved by, for example, Gasser et 
al. by conjugating Re(I) diimine cores to known receptor-targeting peptide conjugates - a short 
nuclear localization signal (NLS), 131, and a derivative of the neuropeptide bombesin, 132 
(Figure 24) [119]. The NLS was conjugated with the aim of localising the PS in the nucleus in 
order to cause DNA damage upon activation, while 132 was designed to target receptors 
overexpressed in certain cancers. The ȍǼ of the two control complexes, which did not contain 
targeting conjugates, 129 and 130,
 
assessed by indirect (RNO/Histidine assay) and direct (NIR 
emission of 1O2) methods were found to be in the range 0.2-0.26 and 0.72-0.79 in water and 
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acetonitrile, respectively. The subcellular localisation of the compounds assessed by emission 
microscopy indicated that 129 localises to the cytoplasm, 130 displays homogeneous 
distribution throughout the cell and 131 specifically locates to the nucleoli. The intracellular 
luminescence from 132 was too weak to evaluate its subcellular localisation. The toxicity of 
compounds 129 – 132 was assessed in HeLa and MCR-5 (human fibroblast) cell lines. 129 and 
130 showed low levels of dark toxicity in both cell lines (LD50 >100 µM). Both 131 and 132 
were relatively toxic to MCR-5 cells (LD50 = 17.8 and 44.1 respectively), while in HeLa cells 
131 was toxic (LD50 = 35.1 µM) yet 132 was not (LD50 >100 µM). All compounds show light 
induced toxicity with UV excitation (350 nm, 2.58 J cm-2), with an important result that 
conjugation to Bombesin led to  ࡱ 20 fold increase in phototoxicity.   
 
Specific targeting of Re(I) complexes was tackled by Lo et al. by conjugating a Re(I) core to a 
fructose group (133 – 134, Figure 24) [120]; the approach used by the same group to target-
delivery of Ir(III) bipyridine D-fructose compounds[80]. Glucose transporters (GLUTs) are 
transmembrane proteins overexpressed in a number of cancers, hence conjugation of metal 
complexes to the fructose moiety might allow one to specifically target these overexpressing 
cells. Photoexcitation of 133 led to long-lived 3MLCT emission (505 – 553 nm) which was not 
affected by addition of the fructose. As with the Ir(III) complexes addition of the sugar led to a 
decrease in lipophilicity and a drop in cellular uptake compared to the sugar-free analogue 
(0.42 mM  vs 1.83 mM for 133 and 134 respectively as determined by ICP-MS). A reduction in 
uptake at 4 °C indicated an energy dependent uptake pathway and both compounds were 
shown to localise to the mitochondria by colocalisation with MitoTracker deep red (Pearson’s 
colocalisation coefficients of 87% and 80%). Both complexes were shown to be somewhat 
toxic in the dark in MCF7 cells (LD50 = 9.6 µM and 3.9 µM for 133 and 134 respectively) and 
demonstrated PS activity following longwave UV radiation (Ȣexc > 365 nm, 30 min) with PIs 
of 4.8 and 13 for 133 and 134 respectively. The yield of singlet oxygen sensitisation was 
determined indirectly, by photo-oxidation of 1,5-dihydroxynapthalene, and found to be 67.7 % 
and 67.1 % for 133 and 134 respectively. To assess relative uptake of the two complexes, a 
number of cell lines were tested, including two breast cancer lines overexpressing fructose 
transporters (MCF-7 and MDA-MB-231), two non-breast cancer cell lines which do not 
overexpress the fructose transporter (A549 and HepG2) alongside two non-cancer cell lines 
(NIH/3T3 and HEK293T). In all cell lines the uptake of the non-fructose containing complex 
134 was higher as expected due to the higher lipophilicity but whilst 134 showed no major 
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difference in uptake between cell lines, the fructose containing 133 showed significantly higher 
uptake in the two breast cancer cell lines. To show that uptake was dependent on the fructose 
the cell lines were incubated with 133, with and without exogenous fructose. It was found that 
exogenous fructose decreased the uptake of 133 only in the cell lines overexpressing the 
fructose transporter.  This finding further indicates the potential for incorporation of fructose as 
a targeting moiety despite the drawbacks in terms of lipophilicity.   
 
The work towards developing PSs which absorb more of the red part of the spectrum than 
traditional Re(I) diimines has been described in a paper from Meggers et al. in 2014 who 
designed derivatives, 136 – 142, of their original compound 135 for this purpose (Figure 25) 
[121]. The substitution of monodentate S-acceptor pyridine ligand in 135 by V-donor PMe3 in 
136, or an imidazole in 137 did not lead to significant change in the absorption maxima. 
However, modifications of the cyclometallating ligand with accepting and donating moieties, 
138 – 142, led to significant changes in the energy of the lowest absorption band, with the 
largest red shift of 49 nm in complex 5 which bears a ȧ-donating –NMe2-group in position 5 
of the indole moiety. Interestingly, introducing a ȧ-donating substituent in position 5 on the 
indole led to complete suppression of ȍǼ (compounds 138 and 139) and to a substantial 
reduction in ȍǼ when -MeO substituent was used (complex 142). Compounds 140 and 141, 
on the other hand, were shown to efficiently produce 1O2 even under excitation in the red 
region of the spectrum ( 620 nm). Compounds 140 – 142 had PS effect in HeLa cells under 
red light excitation (1 hour,  620 nm, 7W LED). The PI of compound 140 was determined as 
33.3 (30 min,  580 nm, 7W LED).   
 
In another approach to developing broadly absorbing Re(I) photosensitisers, Zhao et al. 
employed the same strategy as discussed above for Ir(III) photosensitisers, namely, conjugation 
to a light-absorbing fluorophore, BODIPY (Figure 26)[122]. The ĭǻ of 143 and 145 in DCM 
were 0.16 and 0.06 respectively which is surprisingly low, and was attributed to the increased 
bulk from the Bodipy chromophore. 144 and 143 were found to be somewhat toxic in the dark 
(LD50 = 18.72 µM and 20.63 µM respectively) to the LLC cells used; PI 143 was determined as 
1.59 (625 nm, unknown dose). The number of Re(I) photosensitisers studied to date is 
relatively small, perhaps due to potential toxicity of the standard tricarbonyl moiety, lack of 
strong absorbance in visible/NIR region unless coupled to an additional photosensitiser, and a 
modest, capacity to modulate and enhance two-photon absorption propensity as only one 
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diimine ligand is present in [Re(diimine)(CO)3Cl] vs. polypyridyl Ru(II), Os(II), or Pt(II) 
complexes with multiple diimine ligands. Nonetheless, given the success of Re(I) compounds 
in emission imaging in life sciences, there is a clear potential, especially through selective 
targeting of subcellular structures, for the development of this group of PS in the future.  
7. Ruthenium (II) complexes for photoactivated chemotherapy 
The primary concerns regarding practical development of type I and II PDT is that of light 
delivery, and the requirement for cellular oxygen. The tumour microenvironment in solid 
tumours can be substantially different to that of healthy tissues. Significant differences in the 
vasculature of the tumour, arising due to the growth of neoplastic cells out pacing the process 
of angiogenesis, can result in a restriction in fresh nutrients and oxygen reaching areas of the 
tumour [123, 124]. A natural result of restriction in oxygen coupled with fast paced growth of 
cells is hypoxia. This lack of oxygen renders PDT ineffective in these areas and a breakdown 
of vasculature during PDT treatment combined with the depletion of cellular oxygen by the 
treatment itself can exacerbate the situation [125].  
 
Photoactivated chemotherapy (PACT) in which photosensitisation of cells takes place by the 
oxygen independent type III pathway is an exciting alternative to PDT. As mentioned before 
the early work with TM complexes for PACT focussed on Pt(IV) complexes and has been 
extensively reviewed elsewhere[102-105]. More recently Ru(II) complexes have been explored 
for use as PACT PS[34, 35, 126]. This review does not attempt to cover Ru(II) PACT in any 
great detail however a few select examples are given to summarise the types of approaches 
groups have taken in designing Ru(II) PSs for PACT.  
 
A common design strategy for PACT PS is to design complexes with photolabile, cytotoxic, 
ligands.  In 2011, C. Turro et al. proposed a cationic complex, cis-[Ru(bpy)2(5CNU)2]2+ (bpy = 
2,2’-bipyridine; 5CNU = 5-cyanouracil), for use in PACT (146, Figure 27) [127]. Upon 
irradiation, solvent-ligand exchange efficiently releases the biologically active compound 
5CNU. 5CNU is a derivative of the chemotherapeutic agent 5-fluorouracil. Coordination to the 
Ru(II) complex renders 5CNU inactive and would allow for photo-release at the target site. 
While not reported in cells, the complex was effectively shown to release the chemotherapeutic 
upon visible excitation (Ȝirr  395 nm) demonstrating its potential. Following this work, C. 
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Turro’s group, in collaboration with others, have explored Ru(II) complexes exhibiting photo-
induced ligand release[128-131].  
In 2012 Glazer et al. reported Ru(II) complexes 147 and 148 which have low toxicity in the 
dark, but photo-release a bidentate ligand under visible light (Ȝexc > 450 nm) forming a highly 
toxic, DNA-binding Ru(II) complex 149 (Figure 27)[132]. Chemical analysis confirmed rapid 
dissociation of the sterically strained ligand upon irradiation in 147 and 148 while a non-
sterically strained control compound, 150, was found to be photo-stable. 147 photobinds to 
DNA (visible light, 200 W, 1 hour) while 150 photocleaves DNA and 148 both photobinds to, 
and photocleaves DNA. The PS activity of the compounds was tested in HL60 leukaemia and 
A549 lung cancer cell lines with visible light excitation (Ȝexc > 450 nm, 410 W, 3 min) leading 
to a PI of 208 for 148 in A549 cells. 
 
More recently Kodanko, et al. explored the Ru(II)-caged abiraterone complexes, 151 and 152, 
for photorelease of the potent Cytochrome P450 enzyme (CYP) inhibitor abiraterone (AB) 
(Figure 28)[133]. Abiraterone acetate is an FDA approved therapeutic for metastatic prostate 
cancer however the anti-androgenic action of the drug is not limited to the tumour leading to 
negative effects in healthy tissue. In both 151 and 152 AB is photo-released through ligand 
exchange with the solvent (CH3CN or H2O) with visible light irradiation (Ȝexc 500 nm). The 
bulkier N^N ligand in 151 led to faster photo-release of AB compared to the less sterically 
strained complex 152[35]. Both 151 and 152 were tested in a AB sensitive cell line DU145. 
151 and light (Ȝexc  395 nm, 250 W, 10 min) was deemed as toxic as AB while 151 
administered in the dark showed limited toxicity up to 100 ȝM.  
 
A similar strategy was subsequently used by Bonnet et al. who demonstrated photo-release of a 
cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor from Ru(II) complexes, 
153 and 154 (Figure 28)[134]. NAMPT can be upregulated in cancer cells, with NAMPT 
inhibition able to induce apoptosis in cancer cells. However, the side-effects of NAMPT can 
include blindness making NAMPT inhibitors a good target for photo-release. A known 
inhibitor of NAMPT, STF-31, was coordinated to the same photo-caging scaffold as in [133]. 
Photo-release of STF-31 was demonstrated with both compounds (Ȝexc 625 nm) with 153 more 
efficiently releasing STF-31 as predicted due to the bulkiness of the associated ligand. Both 
153 and 154 were tested in three cancer cell lines (A549, MCF-7, and A431) and a normal cell 
line (MRC-5) in normoxic (21% O2) and hypoxic (1% O2) conditions in the dark and with red 
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light treatment (628 nm, 20.6 J cm-2). 153 proved unsuitable for use due to the lability of STF-
31 in the dark. However, 154 proved promising as a PACT PS with similar PI values in 
normoxic and hypoxic conditions with low dose red light (628 nm, 20.6 J cm-2).  
These findings clearly demonstrate the potential offered by Ru(II) complexes in PACT.   
8. Summary 
The exploration of transition metal complexes as photosensitisers for PDT has seen rapid 
development in the past decade. The diversity of approaches used is immense, clearly 
demonstrating the adaptability of design of TM complexes as PS. Whilst Ru(II) is considered 
the leader in this field, Ir(III) is proving a worthy contestant, with some Os(II), Pt, and Re(I) PS 
emerging as important players as well.  Many TM photosensitisers have demonstrated high 
photoindices, PI = LD50(light)/LD50(dark). It is important to note the practical difficulties of 
comparing efficiency of photosensitisers reported by different laboratories. This difficulty is 
intrinsic to the diversity of light sources used – from pulsed lasers to broad-band arch lamps 
with vastly different spectral characteristics and power densities.  Normalising of the PI 
reported for the light dose used may be the first step to more realistic comparisons between 
different photosensitisers activated by one-photon excitation. Three compounds (Table 1) stand 
out as the most promising ones, demonstrating the best PI/dose parameter of >100: Ir(III) 
complex 52 [77] which is also active under 2-photon excitation, Ir(III) complex 100 [97], and 
Pt(II) compound 117 [108]. Several other PS show PI/dose values between 40 and 10, whilst 
the majority of the photosensitisers have PI/dose values <10. The relatively high two-photon 
absorption cross-sections exhibited by some of metal complexes aids in the development of 
two-photon excitation in PDT. Increased targeting is badly needed to achieve disease 
specificity in patient care. Use of 2-photon PDT, development of complexes which absorb 
more in the red spectral region and/or the addition of targeting moieties to TM complexes 
offers hope for a revolution in the age old use of light for therapy; the first proof of which is 
offered with the advent of the first TM complex in a PDT clinical trial.  
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Table 1. A summary of photophysical data for compounds with highest PI in reviewed literature. NR = not reported. a Subcellular 
localisation: mito = mitochondrial; lyso = lysosomal; PN = perinuclear; Nuc = nuclear; cyto = cytoplasmic; ER = endoplasmic reticulum.  
b Mode of cell death: A = apoptosis; N = necrosis. 
 
Com-
pound  
Metal center LD50 light 
(µM) 
LD50 dark 
(µM) 
PI Ȝexc (nm) Dose  
(J cm-2) 
PI/dose Localisatio
na 
ROS/1O2(Ɍȴ) Cell 
deathb 
One-
/two- 
photon 
ref 
4 Ru(II) 3.5 >100 >28 450 12 2.33 Mito 1O2,0.81   ? both [39]
5 Ru(II) 1.5 470 313 450 10 31.3 Lyso 1O2,0.99 N both ȏ	?	?Ȑ
8 Ru(II) 3.1 36.5 11.7 420 9.27 1.26 NR 1O2,0.75   ? both ȏ	?	?Ȑ
16 Ru(II) 0.206 >300 >1,400 Vislight 100 >14 NR 1O2,0.0056   ? One ȏ	?	?Ȑ
21 Ru(II)/Re(I) 61.7 0.3 206  48 4.29 NM/ER 1O2,0.54 N One ȏ	?	?Ȑ
12 Ru(II) 20 >100 >5 UV ?A 1.29 >3.87 nuclear 1O2 A One ȏ	?	?Ȑ
23 Ru(II) 0.0349 7.7 220 470 6 36.7 Mito 1O2   ? One ȏ	?	?Ȑ
41b Ir(III) 0.23 7.9 34.35 ш450 NR   ? NR   ? A One ȏ	?	?Ȑ
45 Ir(III) 1.6 30.2 18.9 425 7.2 2.625 Cyto 1O2,0.75 A One ȏ	?	?Ȑ
46 Ir(III) NR NR NR TPE800   ?   ? Mito 1O2,0.54   ? TPE ȏ	?	?Ȑ
47 Ir(III) NR NR NR TPE740   ?  ? NR 1O2   ? Both ȏ	?	?Ȑ
51 Ir(III) 0.65 3.67 5.64
sunlight(+
TPE860) <1 >5.64 ER 1O2,0.78 A Both
ȏ	?	?Ȑ
52 Ir(III) 0.18 >100 >555
760TPE
405 3.6 >154.1
Mito+
lyso 1O2,0.42 A Both
ȏ	?	?Ȑ
54 Ir(III) 0.4 30.3 75 405 12 6.25 mito 1O2   ? Both ȏ	?	?Ȑ
57 Ir(III) NR NR NR 808   ?   ? nuclear 1O2 A TPE ȏ	?	?Ȑ
62 Ir(III) 5 >498.4 99.68 >365nm NR   ? mito 1O2,0.409   ? one ȏ	?	?Ȑ
67 Ir(III) 0.5 8.6 17.2 UV ?A 6W1h  ? mito 1O2,0.082   ? one ȏ	?	?Ȑ
70 Ir(III) NR NR NR 475 39.6 
Mito+
lyso ROS+1O2 A+N one
ȏ	?	?Ȑ
72 Ir(III) NR NR NR 377 NR  lyso 1O2 N one ȏ	?	?Ȑ
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Com-
pound  Metal center LD50 light (µM) LD50 dark (µM) PI Ȝexc (nm) Dose  (J cm-2) PI/dose Localisationa ROS/1O2(Ɍȴ) Cell death
b
One-
/two- 
photon
ref
75 Ir(III) 0.12 >100 >833 425nm 36 23.14 lyso
1O20.05
(pH7.4)
0.51(pH3) A one
ȏ	?	?Ȑ
78 Ir(III) 2.58 9.81 3.80 635 NR   ? NR 1O2,0.53   ? one ȏ	?	?Ȑ
87 Ir(III) 0.354 144 407
broadvis
light 100 4.07
Nuc+
cyto   ?   ? one
ȏ	?	?Ȑ
91 Ir(III) 3.4 >300 >88.2 365 NR   ? mito 1O2,0.69 N one ȏ	?	?Ȑ
100 Ir(III) 0.00086 3.1 3488 365 20 174.4 mito 1O2,0.62 A one ȏ	?	?Ȑ
101 Ir(III) NR NR NR Xelamp NR   ? PN   ? A one ȏ	?	?Ȑ
104 Ir(III) NR >300 NR 600nm NR   ? cyto 1O2,0.748   ? one ȏ	?	?Ȑ
106 Ir(III) 0.17 >4 >23 420 9.27 >2.48 mito 1O2,0.87   ? one ȏ	?	?	?Ȑ
113 Ir(III) 0.15 22.5 150 405 6 25 mito 1O2,0.59 A one ȏ	?	?	?Ȑ
117 Pt(II) 0.019 >100 >5260 420 6.95 >756 nuclear 1O2,0.54   ? one ȏ	?	?	?Ȑ
118 Pt(II) 0.2 1.6 8 405 3.6 2.22 nuclear 1O2,0.7   ? one ȏ	?	?	?Ȑ
119 (Os(II))2 ?Rh NR NR NR >460 NR NR NR NR   ? one ȏ	?	?	?Ȑ
122 Os(II)
86.1 >500 >5.8 625 13.5 0.43 NR NR   ? one ȏ	?	?	?Ȑ
50.7 >500 >9.86 470 13.5 0.73 NR NR   ? one
125 Os(II)
57 550 9.6 625 90 0.0154
NR 1O2,0.04   ? both
ȏ	?	?Ȑ
45 550 12.0 808 600 0.02
126 Re(I) 0.1 100 1000 >505 105.12 9.512
membra
ne 1O2 A one
ȏ	?	?	?Ȑ
132 Re(I) 5.3 >100 18.87 350 2.58 7.313 NR 1O2   ? one ȏ	?	?	?Ȑ
134 Re(I) 0.3 3.9 13 >365 NR   ? mito 1O2   ? one ȏ	?	?	?Ȑ
140 Re(I) 0.3 10 33 >580 NR   ? NR 1O2   ? one ȏ	?	?	?Ȑ
143 Re(I) 12.94 20.63 1.59 625 NR   ? NR 1O2,0.16   ? one ȏ	?	?	?Ȑ
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Figure captions.  
 
Figure 1. A schematic of PDT treatment of cancer: a) non-active form of drug is 
administered; b) drug is left to accumulate in tumour and healthy tissue; c) specific 
radiation of tumour tissue leads to production of singlet oxygen/ reactive oxygen species 
leading to targeted cell death. Top left: Depth of tissue penetration by varying wavelengths 
of light [2]. 
 
Figure 2. a) Structure of Psoralen and related molecules, adapted from [135]; b) Structure 
of Photofrin. 
 
Figure 3. A simplified Jablonski diagram showing typical energy levels and transitions 
relevant to the formation of the triplet state of photosensitiser, and photosensitization of 
molecular oxygen. IC = internal conversion, VR = vibrational relaxation, ISC = intersystem 
crossing. 
 
Figure 4. TLD1433 and examples of several other Ru(II) diimine photosensitisers. 1 - 4 are 
highly lypophylic compounds, numbered RuL1-RuL4 in [39]; compounds 5 - 7 are highly 
charged (+8) compounds (Ru1 – Ru3 in [40]); compounds 8 and 9 that contain derivatives 
of a known DNA intercalating ligand dppz are compounds 1 and 2 in [41]. 
 
Figure 5. Ru(II) photosensitisers 10 and 11 which in conjunction with single wall carbon 
nanotubes act as dual photothermal anticancer agents (compounds Ru1 and Ru2 in [42]). 
 
Figure 6. Chemical structures of some Ru(II) photosensitisers.  Compound 12 (Ru65 in 
[43]) is a DNA intercalator. Compounds 13 - 20 (1 - 8 in [45]) contain cyclometallating and 
diimine ligands. A systematic study of the effect of the extending conjugation in either 
cyclometalalting, or diimine ligands, on photodynamic properties has been performed. 
 
Figure 7. Chemical structures of a macrocyclic Ru(II)/Re(I) photosensitiser 21, and its 
mononuclear Ru(II) building block 22 [46]; Ru(II) PS conjugated to human serum albumin 
(23) cHSA-PEO-TTP-Ru and to HSA aa 312 to 324 (24).[47] 
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Figure 8. Cyclometallated Ir(III) complexes of general type [Ir(C^N)2(NN)]+. 
Compounds 25 and 26 are compounds 1 and 2 in [65]; compounds 27 – 32 are compounds 
1-6 in [56]. Emission images of HeLa cells incubated with 27-31 (left to right) are also 
shown. 
 
Figure 9. Chemical structures of metallo-pyrido carbazole Ir(III) photosensitisers 33 – 41b 
(compounds 1 - 11 in ȏ	?	?Ȑ). 
 
Figure 10. [Ir(C^N)2(NN)]+ photosensitisers designed with the aim of combining 
photosensitisation with a Histone deacetylases (HDAC) inhibitor, suberanilohydroxamic 
acid (SAHA). Compounds 42 - 45 are compounds 1 - 4 in ȏ	?	?Ȑ. The bottom panel shows 
characterisation of apoptosis induced in HeLa by complex 42 using annexin V-FITC 
staining, and monitored by flow cytometry.  
 
Figure 11a. Chemical structures of some [Ir(C^N)2(NN)]+ photosensitisers: 46ȏ	?	?Ȑ; 47ȏ	?	?Ȑ; 
48 - 51 (compounds TIr1 - TIr4 in ȏ	?	?Ȑ).  
Figure 11b. Chemical structures of Ir(III) complexes 52 and 53; emission properties of 52 
are pH sensitive in the physiological range. 52 has the higher PI index for Ir(III) complexes 
to date under one-photon excitation, and is also a two-photon PDT agentȏ	?	?Ȑ. The bottom 
panel shows two photon absorption activated killing of HeLa cancer cells incubated with 52 
(1 ȝM) for two hours, followed by irradiation with 760 nm, ~100 fs pulses (irradiated area 
225 x 225 ȝm, 1024 x 1024 pixels, 6.6 ȝs dwell time, 8 scans) with the powers 
corresponding to 0, 1088, 1632, 2176 J cm-2. Cell apoptosis is indicated in green, necrosis 
in red. Images are 450 x 450 ȝm except those in the 0 mW column which are 900 x 900 
ȝm. 
 
Figure 12. Chemical structures of some of Ir(III) photosensitisers: compounds 54 - 56 are 
compounds Ir1 – Ir3 in ȏ	?	?Ȑ; compounds 57 – 61 are compounds Ir-Es, Ir-Me, Ir-Pn, Ir-Pc 
and Ir-Cz in ȏ	?	?Ȑ.  
 
Figure 13. Ir(III) photosensitisers containing fructose, and their fructose-free analogues; 
compounds 62 – 65 are compounds 1a, 1b, 2a and 2b from ȏ	?	?ȐǤ 
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Figure 14. Ir(III) photosensitisers with diverse cyclometallating ligands. Compounds 66 – 
69 are compounds 1a, 2a, 1b and 2b from ȏ	?	?ȐǤ 
 
Figure 15. Ir(III) photosensitisers which are lysosome-specific (70 and 71, correspond to  
Ir-P(ph)3 and Ir-alkyl from ȏ	?	?Ȑ); [Ir(N^C)3]n pH-responsive photosensitisers 72 and 73 (5 
and H3.5 from ȏ	?	?Ȑ); and pH-responsive, lysosome-specific [Ir(N^C)2(NN)]+ compounds 
74 – 77 (compounds 1 – 4 from ȏ	?	?Ȑ). 
 
Figure 16. Red-light activated Ir(III) photosensitisers bearing BODIPY groups, 78 – 81 
(compounds Ir-1 – Ir-2 from ȏ	?	?Ȑ). 
 
Figure 17. Systematic tuning of light-absorbing properties of Ir(III) complexes through 
changing conjugation in diimine and cyclometalling ligands, 82 – 87 (compounds 1 – 6 
from ȏ	?	?Ȑ). 
 
Figure 18. Ir(III) photosensitisers with PEG chains and their analogs. Compounds 88 – 92 
are compounds 1a – 5a, compounds 93 – 97 are compounds 1b – 5b from ȏ	?	?ȐǤ 
 
Figure 19. Ir(III) photosensitisers designed for mitochondrial (98 – 100, compounds 1 – 3 
from ȏ	?	?Ȑ) and perinuclear (101 – 102, compounds 1M and 1P from ȏ	?	?Ȑ ) localisation. 
 
Figure 20. Orange-absorbing photosensitisers 103 and 104 (Ru-2 and Ir-2 from ȏ	?	?Ȑ); 
aromatic acid imide-containing photosensitisers 105 - 108 (R1, R2, L1 and L2 from ȏ	?	?	?Ȑ); 
mitochondria-targeting photosensitisers 109 – 113 (Ir1 – Ir5 from ȏ	?	?	?Ȑ). 
 
Figure 21. Pt-based photosensitisers. 114 – 117 are compounds 1 – 4 from ȏ	?	?	?Ȑ; 
compound 118 is compound 1 from ȏ	?	?	?Ȑ. The bottom panel shows a representative 
COMET assay images for HeLa cells treated with 0.5 PM of 118, with and without 
exposure to 405 nm light (3.6 J cm-2). 
 
Figure 22. Multinuclear Os and Ru photosensitisers 119 and 120 ȏ	?	?	?Ȑ; mononuclear 
Ru(II) and Os(II) photosensitisers 121 and 122 (1 and 2 from ȏ	?	?	?Ȑ). 
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Figure 23. Os(II) photosensitisers 123 – 125 (TLD1822, TLD1824 and TLD1829 from ȏ	?	?Ȑ).  Re(I) photosensitisers 126 – 127 (1 -4 from ȏ	?	?	?Ȑ).  
 
Figure 24. Re(I) photosensitisers bearing protein tags, 129 – 132 (Re –NH2, Re-COOH, 
Re-NLS and Re-Bombesin from ȏ	?	?	?Ȑ) and fructose unit, 133 - 134 (1 and 2 from ȏ	?	?	?Ȑ), 
and their tag-free analogs. 
 
Figure 25. Re(I) pyridocarbazole complexes with tuneable absorption maxima for red-light 
activated PDT, 135 – 142 (compounds 1 – 8 fromȏ	?	?	?ȐȌǢcompounds 138-139 are not PDT-
active. The bottom panel shows visible-light-induced antiproliferative activity of 140 in 
HeLa cancer cells which were irradiated for 30 min at Ȝ  580 nm following 1 h incubation 
with 140; cytotoxicity was determined 24 h after addition by MTT assay.   
 
Figure 26. Re(I) photosensitisers 143 and 145 containing BODIPY unit (Re–1 and Re-2 
from ȏ	?	?	?Ȑ). 
 
Figure 27. Ru(II) photosensitisers 146 (1 in [127]) and 147-149 (2, 3 and 1 in [132]), and a 
control compound 150. 
 
Figure 28. Ru(II) photosensitisers 151 and 152 (1 and 2 in [133]) and 153 and 154 (1 and 2 
in [134]). 
